{"id": "AIMed.d104.s878_AIMed.d104.s878.p0", "text": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.", "text_with_entity_marker": "This transcriptional activity is inhibited by association with the [E1]retinoblastoma tumor suppressor protein[/E1] ([E2]pRB[/E2]) or its relatives p107 and p103.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma tumor suppressor protein", "entity_1_idx": [[67, 106]], "entity_1_idx_in_text_with_entity_marker": [71, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[108, 111]], "entity_2_idx_in_text_with_entity_marker": [121, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s878_AIMed.d104.s878.p1", "text": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.", "text_with_entity_marker": "This transcriptional activity is inhibited by association with the [E1]retinoblastoma tumor suppressor protein[/E1] (pRB) or its relatives [E2]p107[/E2] and p103.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma tumor suppressor protein", "entity_1_idx": [[67, 106]], "entity_1_idx_in_text_with_entity_marker": [71, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s878_AIMed.d104.s878.p2", "text": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.", "text_with_entity_marker": "This transcriptional activity is inhibited by association with the [E1]retinoblastoma tumor suppressor protein[/E1] (pRB) or its relatives p107 and [E2]p103[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma tumor suppressor protein", "entity_1_idx": [[67, 106]], "entity_1_idx_in_text_with_entity_marker": [71, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p103", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s878_AIMed.d104.s878.p3", "text": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.", "text_with_entity_marker": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ([E1]pRB[/E1]) or its relatives [E2]p107[/E2] and p103.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[108, 111]], "entity_1_idx_in_text_with_entity_marker": [112, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[130, 134]], "entity_2_idx_in_text_with_entity_marker": [143, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s878_AIMed.d104.s878.p4", "text": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.", "text_with_entity_marker": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein ([E1]pRB[/E1]) or its relatives p107 and [E2]p103[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[108, 111]], "entity_1_idx_in_text_with_entity_marker": [112, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p103", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s878_AIMed.d104.s878.p5", "text": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives p107 and p103.", "text_with_entity_marker": "This transcriptional activity is inhibited by association with the retinoblastoma tumor suppressor protein (pRB) or its relatives [E1]p107[/E1] and [E2]p103[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p107", "entity_1_idx": [[130, 134]], "entity_1_idx_in_text_with_entity_marker": [134, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p103", "entity_2_idx": [[139, 143]], "entity_2_idx_in_text_with_entity_marker": [152, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s879_AIMed.d104.s879.p0", "text": "The first cDNA from the E2F family to be cloned was designated E2F-1, and multiple E2F family members have now been identified.", "text_with_entity_marker": "The first cDNA from the [E1]E2F[/E1] family to be cloned was designated [E2]E2F-1[/E2], and multiple E2F family members have now been identified.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F-1", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s879_AIMed.d104.s879.p1", "text": "The first cDNA from the E2F family to be cloned was designated E2F-1, and multiple E2F family members have now been identified.", "text_with_entity_marker": "The first cDNA from the [E1]E2F[/E1] family to be cloned was designated E2F-1, and multiple [E2]E2F[/E2] family members have now been identified.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[83, 86]], "entity_2_idx_in_text_with_entity_marker": [96, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s879_AIMed.d104.s879.p2", "text": "The first cDNA from the E2F family to be cloned was designated E2F-1, and multiple E2F family members have now been identified.", "text_with_entity_marker": "The first cDNA from the E2F family to be cloned was designated [E1]E2F-1[/E1], and multiple [E2]E2F[/E2] family members have now been identified.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F-1", "entity_1_idx": [[63, 68]], "entity_1_idx_in_text_with_entity_marker": [67, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[83, 86]], "entity_2_idx_in_text_with_entity_marker": [96, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s881_AIMed.d104.s881.p0", "text": "Here we demonstrate that DP is also a family of polypeptides with at least two members (hDP-1 and hDP-2).", "text_with_entity_marker": "Here we demonstrate that DP is also a family of polypeptides with at least two members ([E1]hDP-1[/E1] and [E2]hDP-2[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hDP-1", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hDP-2", "entity_2_idx": [[98, 103]], "entity_2_idx_in_text_with_entity_marker": [111, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s882_AIMed.d104.s882.p0", "text": "Both hDP-1 and hDP-2 bind to all E2F family members in vivo, and each complex is capable of activating transcription.", "text_with_entity_marker": "Both [E1]hDP-1[/E1] and [E2]hDP-2[/E2] bind to all E2F family members in vivo, and each complex is capable of activating transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hDP-1", "entity_1_idx": [[5, 10]], "entity_1_idx_in_text_with_entity_marker": [9, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hDP-2", "entity_2_idx": [[15, 20]], "entity_2_idx_in_text_with_entity_marker": [28, 33], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s882_AIMed.d104.s882.p1", "text": "Both hDP-1 and hDP-2 bind to all E2F family members in vivo, and each complex is capable of activating transcription.", "text_with_entity_marker": "Both [E1]hDP-1[/E1] and hDP-2 bind to all [E2]E2F[/E2] family members in vivo, and each complex is capable of activating transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hDP-1", "entity_1_idx": [[5, 10]], "entity_1_idx_in_text_with_entity_marker": [9, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[33, 36]], "entity_2_idx_in_text_with_entity_marker": [46, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s882_AIMed.d104.s882.p2", "text": "Both hDP-1 and hDP-2 bind to all E2F family members in vivo, and each complex is capable of activating transcription.", "text_with_entity_marker": "Both hDP-1 and [E1]hDP-2[/E1] bind to all [E2]E2F[/E2] family members in vivo, and each complex is capable of activating transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "hDP-2", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[33, 36]], "entity_2_idx_in_text_with_entity_marker": [46, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p0", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various [E1]E2F[/E1]/DP complexes display strong differences in the ability to bind to either [E2]pRB[/E2] or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[98, 101]], "entity_2_idx_in_text_with_entity_marker": [111, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p1", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various [E1]E2F[/E1]/DP complexes display strong differences in the ability to bind to either pRB or [E2]p107[/E2] in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[105, 109]], "entity_2_idx_in_text_with_entity_marker": [118, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p2", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various [E1]E2F[/E1]/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of [E2]pRB[/E2] or p107 binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p3", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various [E1]E2F[/E1]/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or [E2]p107[/E2] binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[149, 153]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p4", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various [E1]E2F[/E1]/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the [E2]E2F[/E2] subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "E2F", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p5", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either [E1]pRB[/E1] or [E2]p107[/E2] in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[105, 109]], "entity_2_idx_in_text_with_entity_marker": [118, 122], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p6", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either [E1]pRB[/E1] or p107 in vivo, and the specificity of [E2]pRB[/E2] or p107 binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p7", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either [E1]pRB[/E1] or p107 in vivo, and the specificity of pRB or [E2]p107[/E2] binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[149, 153]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p8", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either [E1]pRB[/E1] or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the [E2]E2F[/E2] subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[98, 101]], "entity_1_idx_in_text_with_entity_marker": [102, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p9", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or [E1]p107[/E1] in vivo, and the specificity of [E2]pRB[/E2] or p107 binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p107", "entity_1_idx": [[105, 109]], "entity_1_idx_in_text_with_entity_marker": [109, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p10", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or [E1]p107[/E1] in vivo, and the specificity of pRB or [E2]p107[/E2] binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p107", "entity_1_idx": [[105, 109]], "entity_1_idx_in_text_with_entity_marker": [109, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[149, 153]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p11", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or [E1]p107[/E1] in vivo, and the specificity of pRB or p107 binding is mediated by the [E2]E2F[/E2] subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p107", "entity_1_idx": [[105, 109]], "entity_1_idx_in_text_with_entity_marker": [109, 113], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p12", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of [E1]pRB[/E1] or [E2]p107[/E2] binding is mediated by the E2F subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p107", "entity_2_idx": [[149, 153]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p13", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of [E1]pRB[/E1] or p107 binding is mediated by the [E2]E2F[/E2] subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pRB", "entity_1_idx": [[142, 145]], "entity_1_idx_in_text_with_entity_marker": [146, 149], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d104.s883_AIMed.d104.s883.p14", "text": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or p107 binding is mediated by the E2F subunit.", "text_with_entity_marker": "However, the various E2F/DP complexes display strong differences in the ability to bind to either pRB or p107 in vivo, and the specificity of pRB or [E1]p107[/E1] binding is mediated by the [E2]E2F[/E2] subunit.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p107", "entity_1_idx": [[149, 153]], "entity_1_idx_in_text_with_entity_marker": [153, 157], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E2F", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s652_AIMed.d77.s652.p0", "text": "Desmoplakin (DPI), a desmosomal component lacking a transmembrane domain, has been implicated in this interaction, although most studies have been conducted with cells that contain few or no desmosomes, and efforts to demonstrate direct interactions between desmoplakin and intermediate filaments have not been successful.", "text_with_entity_marker": "[E1]Desmoplakin[/E1] ([E2]DPI[/E2]), a desmosomal component lacking a transmembrane domain, has been implicated in this interaction, although most studies have been conducted with cells that contain few or no desmosomes, and efforts to demonstrate direct interactions between desmoplakin and intermediate filaments have not been successful.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Desmoplakin", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPI", "entity_2_idx": [[13, 16]], "entity_2_idx_in_text_with_entity_marker": [26, 29], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p0", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of [E1]DPI[/E1] associates directly with the amino terminal \"head\" of type II epidermal keratins, including [E2]K1[/E2], K2, K5, and K6.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DPI", "entity_1_idx": [[44, 47]], "entity_1_idx_in_text_with_entity_marker": [48, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K1", "entity_2_idx": [[140, 142]], "entity_2_idx_in_text_with_entity_marker": [153, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p1", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of [E1]DPI[/E1] associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, [E2]K2[/E2], K5, and K6.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DPI", "entity_1_idx": [[44, 47]], "entity_1_idx_in_text_with_entity_marker": [48, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K2", "entity_2_idx": [[144, 146]], "entity_2_idx_in_text_with_entity_marker": [157, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p2", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of [E1]DPI[/E1] associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, [E2]K5[/E2], and K6.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DPI", "entity_1_idx": [[44, 47]], "entity_1_idx_in_text_with_entity_marker": [48, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K5", "entity_2_idx": [[148, 150]], "entity_2_idx_in_text_with_entity_marker": [161, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p3", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of [E1]DPI[/E1] associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and [E2]K6[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "DPI", "entity_1_idx": [[44, 47]], "entity_1_idx_in_text_with_entity_marker": [48, 51], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K6", "entity_2_idx": [[156, 158]], "entity_2_idx_in_text_with_entity_marker": [169, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p4", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including [E1]K1[/E1], [E2]K2[/E2], K5, and K6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K1", "entity_1_idx": [[140, 142]], "entity_1_idx_in_text_with_entity_marker": [144, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K2", "entity_2_idx": [[144, 146]], "entity_2_idx_in_text_with_entity_marker": [157, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p5", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including [E1]K1[/E1], K2, [E2]K5[/E2], and K6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K1", "entity_1_idx": [[140, 142]], "entity_1_idx_in_text_with_entity_marker": [144, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K5", "entity_2_idx": [[148, 150]], "entity_2_idx_in_text_with_entity_marker": [161, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p6", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including [E1]K1[/E1], K2, K5, and [E2]K6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K1", "entity_1_idx": [[140, 142]], "entity_1_idx_in_text_with_entity_marker": [144, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K6", "entity_2_idx": [[156, 158]], "entity_2_idx_in_text_with_entity_marker": [169, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p7", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, [E1]K2[/E1], [E2]K5[/E2], and K6.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K2", "entity_1_idx": [[144, 146]], "entity_1_idx_in_text_with_entity_marker": [148, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K5", "entity_2_idx": [[148, 150]], "entity_2_idx_in_text_with_entity_marker": [161, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p8", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, [E1]K2[/E1], K5, and [E2]K6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K2", "entity_1_idx": [[144, 146]], "entity_1_idx_in_text_with_entity_marker": [148, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K6", "entity_2_idx": [[156, 158]], "entity_2_idx_in_text_with_entity_marker": [169, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s654_AIMed.d77.s654.p9", "text": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, K5, and K6.", "text_with_entity_marker": "We show that the carboxy terminal \"tail\" of DPI associates directly with the amino terminal \"head\" of type II epidermal keratins, including K1, K2, [E1]K5[/E1], and [E2]K6[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "K5", "entity_1_idx": [[148, 150]], "entity_1_idx_in_text_with_entity_marker": [152, 154], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "K6", "entity_2_idx": [[156, 158]], "entity_2_idx_in_text_with_entity_marker": [169, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s655_AIMed.d77.s655.p0", "text": "We have engineered and purified recombinant K5 head and DPI tail, and we demonstrate direct interaction in vitro by solution-binding assays and by ligand blot assays.", "text_with_entity_marker": "We have engineered and purified recombinant [E1]K5[/E1] head and [E2]DPI[/E2] tail, and we demonstrate direct interaction in vitro by solution-binding assays and by ligand blot assays.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "K5", "entity_1_idx": [[44, 46]], "entity_1_idx_in_text_with_entity_marker": [48, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPI", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d77.s657_AIMed.d77.s657.p0", "text": "We have identified an 18-amino acid residue stretch in the K5 head that is conserved only among type II epidermal keratins and that appears to play some role in DPI tail binding.", "text_with_entity_marker": "We have identified an 18-amino acid residue stretch in the [E1]K5[/E1] head that is conserved only among type II epidermal keratins and that appears to play some role in [E2]DPI[/E2] tail binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "K5", "entity_1_idx": [[59, 61]], "entity_1_idx_in_text_with_entity_marker": [63, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DPI", "entity_2_idx": [[161, 164]], "entity_2_idx_in_text_with_entity_marker": [174, 177], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s419_AIMed.d48.s419.p0", "text": "LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.", "text_with_entity_marker": "[E1]LEC[/E1] induces chemotaxis and adhesion by interacting with [E2]CCR1[/E2] and CCR8.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s419_AIMed.d48.s419.p1", "text": "LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.", "text_with_entity_marker": "[E1]LEC[/E1] induces chemotaxis and adhesion by interacting with CCR1 and [E2]CCR8[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR8", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s419_AIMed.d48.s419.p2", "text": "LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.", "text_with_entity_marker": "LEC induces chemotaxis and adhesion by interacting with [E1]CCR1[/E1] and [E2]CCR8[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR8", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p0", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "[E1]Liver-expressed chemokine[/E1] ([E2]LEC[/E2]) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Liver-expressed chemokine", "entity_1_idx": [[0, 25]], "entity_1_idx_in_text_with_entity_marker": [4, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEC", "entity_2_idx": [[27, 30]], "entity_2_idx_in_text_with_entity_marker": [40, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p1", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "[E1]Liver-expressed chemokine[/E1] (LEC) is an unusually large CC chemokine, which is also known as [E2]LMC[/E2], HCC-4, NCC-4, and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Liver-expressed chemokine", "entity_1_idx": [[0, 25]], "entity_1_idx_in_text_with_entity_marker": [4, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LMC", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p2", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "[E1]Liver-expressed chemokine[/E1] (LEC) is an unusually large CC chemokine, which is also known as LMC, [E2]HCC-4[/E2], NCC-4, and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Liver-expressed chemokine", "entity_1_idx": [[0, 25]], "entity_1_idx_in_text_with_entity_marker": [4, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HCC-4", "entity_2_idx": [[96, 101]], "entity_2_idx_in_text_with_entity_marker": [109, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p3", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "[E1]Liver-expressed chemokine[/E1] (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, [E2]NCC-4[/E2], and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Liver-expressed chemokine", "entity_1_idx": [[0, 25]], "entity_1_idx_in_text_with_entity_marker": [4, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NCC-4", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p4", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "[E1]Liver-expressed chemokine[/E1] (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and [E2]CCL16[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Liver-expressed chemokine", "entity_1_idx": [[0, 25]], "entity_1_idx_in_text_with_entity_marker": [4, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p5", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine ([E1]LEC[/E1]) is an unusually large CC chemokine, which is also known as [E2]LMC[/E2], HCC-4, NCC-4, and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LMC", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p6", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine ([E1]LEC[/E1]) is an unusually large CC chemokine, which is also known as LMC, [E2]HCC-4[/E2], NCC-4, and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HCC-4", "entity_2_idx": [[96, 101]], "entity_2_idx_in_text_with_entity_marker": [109, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p7", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine ([E1]LEC[/E1]) is an unusually large CC chemokine, which is also known as LMC, HCC-4, [E2]NCC-4[/E2], and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NCC-4", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p8", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine ([E1]LEC[/E1]) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and [E2]CCL16[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p9", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as [E1]LMC[/E1], [E2]HCC-4[/E2], NCC-4, and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LMC", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HCC-4", "entity_2_idx": [[96, 101]], "entity_2_idx_in_text_with_entity_marker": [109, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p10", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as [E1]LMC[/E1], HCC-4, [E2]NCC-4[/E2], and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LMC", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NCC-4", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p11", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as [E1]LMC[/E1], HCC-4, NCC-4, and [E2]CCL16[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LMC", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p12", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, [E1]HCC-4[/E1], [E2]NCC-4[/E2], and CCL16.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HCC-4", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NCC-4", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p13", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, [E1]HCC-4[/E1], NCC-4, and [E2]CCL16[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HCC-4", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s420_AIMed.d48.s420.p14", "text": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.", "text_with_entity_marker": "Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, [E1]NCC-4[/E1], and [E2]CCL16[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NCC-4", "entity_1_idx": [[103, 108]], "entity_1_idx_in_text_with_entity_marker": [107, 112], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCL16", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s422_AIMed.d48.s422.p0", "text": "We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK-293 cells.", "text_with_entity_marker": "We report chemotaxis and competitive binding studies that show [E1]LEC[/E1] binds to and activates [E2]CCR1[/E2] and CCR8 transfected HEK-293 cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[63, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[90, 94]], "entity_2_idx_in_text_with_entity_marker": [103, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s422_AIMed.d48.s422.p1", "text": "We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK-293 cells.", "text_with_entity_marker": "We report chemotaxis and competitive binding studies that show [E1]LEC[/E1] binds to and activates CCR1 and [E2]CCR8[/E2] transfected HEK-293 cells.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LEC", "entity_1_idx": [[63, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR8", "entity_2_idx": [[99, 103]], "entity_2_idx_in_text_with_entity_marker": [112, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s422_AIMed.d48.s422.p2", "text": "We report chemotaxis and competitive binding studies that show LEC binds to and activates CCR1 and CCR8 transfected HEK-293 cells.", "text_with_entity_marker": "We report chemotaxis and competitive binding studies that show LEC binds to and activates [E1]CCR1[/E1] and [E2]CCR8[/E2] transfected HEK-293 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[90, 94]], "entity_1_idx_in_text_with_entity_marker": [94, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR8", "entity_2_idx": [[99, 103]], "entity_2_idx_in_text_with_entity_marker": [112, 116], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s423_AIMed.d48.s423.p0", "text": "LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.", "text_with_entity_marker": "[E1]LEC[/E1] induced maximal migration of [E2]CCR1[/E2] and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR1", "entity_2_idx": [[33, 37]], "entity_2_idx_in_text_with_entity_marker": [46, 50], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s423_AIMed.d48.s423.p1", "text": "LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.", "text_with_entity_marker": "[E1]LEC[/E1] induced maximal migration of CCR1 and [E2]CCR8[/E2] transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR8", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s423_AIMed.d48.s423.p2", "text": "LEC induced maximal migration of CCR1 and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.", "text_with_entity_marker": "LEC induced maximal migration of [E1]CCR1[/E1] and [E2]CCR8[/E2] transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR1", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR8", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s424_AIMed.d48.s424.p0", "text": "The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or I309, respectively.", "text_with_entity_marker": "The molar concentration of [E1]LEC[/E1] required to induce maximum cell migration is 20- to 200-fold greater than that required for [E2]RANTES[/E2] or I309, respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RANTES", "entity_2_idx": [[123, 129]], "entity_2_idx_in_text_with_entity_marker": [136, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s424_AIMed.d48.s424.p1", "text": "The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or I309, respectively.", "text_with_entity_marker": "The molar concentration of [E1]LEC[/E1] required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or [E2]I309[/E2], respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "I309", "entity_2_idx": [[133, 137]], "entity_2_idx_in_text_with_entity_marker": [146, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s424_AIMed.d48.s424.p2", "text": "The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or I309, respectively.", "text_with_entity_marker": "The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for [E1]RANTES[/E1] or [E2]I309[/E2], respectively.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RANTES", "entity_1_idx": [[123, 129]], "entity_1_idx_in_text_with_entity_marker": [127, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "I309", "entity_2_idx": [[133, 137]], "entity_2_idx_in_text_with_entity_marker": [146, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s426_AIMed.d48.s426.p0", "text": "A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.", "text_with_entity_marker": "A neutralizing polyclonal antibody to [E1]LEC[/E1] was developed to demonstrate that the unusually high concentration of [E2]LEC[/E2] required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEC", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s426_AIMed.d48.s426.p1", "text": "A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.", "text_with_entity_marker": "A neutralizing polyclonal antibody to [E1]LEC[/E1] was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of [E2]LEC[/E2] and not as a result of an irrelevant protein contamination.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEC", "entity_2_idx": [[164, 167]], "entity_2_idx_in_text_with_entity_marker": [177, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d48.s426_AIMed.d48.s426.p2", "text": "A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.", "text_with_entity_marker": "A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of [E1]LEC[/E1] required to induce chemotaxis was a property of [E2]LEC[/E2] and not as a result of an irrelevant protein contamination.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LEC", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "LEC", "entity_2_idx": [[164, 167]], "entity_2_idx_in_text_with_entity_marker": [177, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1561_AIMed.d184.s1561.p0", "text": "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.", "text_with_entity_marker": "[E1]CD4[/E1]-induced interaction of primary HIV-1 [E2]gp120[/E2] glycoproteins with the chemokine receptor CCR-5.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD4", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp120", "entity_2_idx": [[41, 46]], "entity_2_idx_in_text_with_entity_marker": [54, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1561_AIMed.d184.s1561.p1", "text": "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.", "text_with_entity_marker": "[E1]CD4[/E1]-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor [E2]CCR-5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[89, 94]], "entity_2_idx_in_text_with_entity_marker": [102, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1561_AIMed.d184.s1561.p2", "text": "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.", "text_with_entity_marker": "CD4-induced interaction of primary HIV-1 [E1]gp120[/E1] glycoproteins with the chemokine receptor [E2]CCR-5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[89, 94]], "entity_2_idx_in_text_with_entity_marker": [102, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1562_AIMed.d184.s1562.p0", "text": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).", "text_with_entity_marker": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, [E1]CCR-5[/E1] and [E2]CXCR-4[/E2], respectively, as well as the primary receptor CD4 (refs 1-6).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[174, 179]], "entity_1_idx_in_text_with_entity_marker": [178, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR-4", "entity_2_idx": [[184, 190]], "entity_2_idx_in_text_with_entity_marker": [197, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1562_AIMed.d184.s1562.p1", "text": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).", "text_with_entity_marker": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, [E1]CCR-5[/E1] and CXCR-4, respectively, as well as the primary receptor [E2]CD4[/E2] (refs 1-6).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[174, 179]], "entity_1_idx_in_text_with_entity_marker": [178, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[238, 241]], "entity_2_idx_in_text_with_entity_marker": [251, 254], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1562_AIMed.d184.s1562.p2", "text": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).", "text_with_entity_marker": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and [E1]CXCR-4[/E1], respectively, as well as the primary receptor [E2]CD4[/E2] (refs 1-6).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CXCR-4", "entity_1_idx": [[184, 190]], "entity_1_idx_in_text_with_entity_marker": [188, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[238, 241]], "entity_2_idx_in_text_with_entity_marker": [251, 254], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p0", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of [E1]gp120[/E1], the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble [E2]CD4[/E2] interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp120", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p1", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of [E1]gp120[/E1], the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with [E2]CCR-5[/E2] and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp120", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[153, 158]], "entity_2_idx_in_text_with_entity_marker": [166, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p2", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of [E1]gp120[/E1], the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural [E2]CCR-5[/E2] ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p3", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of [E1]gp120[/E1], the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, [E2]macrophage inflammatory protein (MIP)-1alpha[/E2] and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "macrophage inflammatory protein (MIP)-1alpha", "entity_2_idx": [[214, 258]], "entity_2_idx_in_text_with_entity_marker": [227, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p4", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of [E1]gp120[/E1], the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and [E2]MIP-1beta[/E2] (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[31, 36]], "entity_1_idx_in_text_with_entity_marker": [35, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[263, 272]], "entity_2_idx_in_text_with_entity_marker": [276, 285], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p5", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble [E1]CD4[/E1] interacts specifically with [E2]CCR-5[/E2] and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD4", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[153, 158]], "entity_2_idx_in_text_with_entity_marker": [166, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p6", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble [E1]CD4[/E1] interacts specifically with CCR-5 and inhibits the binding of the natural [E2]CCR-5[/E2] ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p7", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble [E1]CD4[/E1] interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, [E2]macrophage inflammatory protein (MIP)-1alpha[/E2] and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "macrophage inflammatory protein (MIP)-1alpha", "entity_2_idx": [[214, 258]], "entity_2_idx_in_text_with_entity_marker": [227, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p8", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble [E1]CD4[/E1] interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and [E2]MIP-1beta[/E2] (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[263, 272]], "entity_2_idx_in_text_with_entity_marker": [276, 285], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p9", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with [E1]CCR-5[/E1] and inhibits the binding of the natural [E2]CCR-5[/E2] ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[199, 204]], "entity_2_idx_in_text_with_entity_marker": [212, 217], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p10", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with [E1]CCR-5[/E1] and inhibits the binding of the natural CCR-5 ligands, [E2]macrophage inflammatory protein (MIP)-1alpha[/E2] and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "macrophage inflammatory protein (MIP)-1alpha", "entity_2_idx": [[214, 258]], "entity_2_idx_in_text_with_entity_marker": [227, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p11", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with [E1]CCR-5[/E1] and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and [E2]MIP-1beta[/E2] (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[263, 272]], "entity_2_idx_in_text_with_entity_marker": [276, 285], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p12", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural [E1]CCR-5[/E1] ligands, [E2]macrophage inflammatory protein (MIP)-1alpha[/E2] and MIP-1beta (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[199, 204]], "entity_1_idx_in_text_with_entity_marker": [203, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "macrophage inflammatory protein (MIP)-1alpha", "entity_2_idx": [[214, 258]], "entity_2_idx_in_text_with_entity_marker": [227, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p13", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural [E1]CCR-5[/E1] ligands, macrophage inflammatory protein (MIP)-1alpha and [E2]MIP-1beta[/E2] (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[199, 204]], "entity_1_idx_in_text_with_entity_marker": [203, 208], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[263, 272]], "entity_2_idx_in_text_with_entity_marker": [276, 285], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1563_AIMed.d184.s1563.p14", "text": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta (refs 7, 8).", "text_with_entity_marker": "Here we show that a complex of gp120, the exterior envelope glycoprotein, of macrophage-tropic primary HIV-1 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands, [E1]macrophage inflammatory protein (MIP)-1alpha[/E1] and [E2]MIP-1beta[/E2] (refs 7, 8).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "macrophage inflammatory protein (MIP)-1alpha", "entity_1_idx": [[214, 258]], "entity_1_idx_in_text_with_entity_marker": [218, 262], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MIP-1beta", "entity_2_idx": [[263, 272]], "entity_2_idx_in_text_with_entity_marker": [276, 285], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1564_AIMed.d184.s1564.p0", "text": "The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4.", "text_with_entity_marker": "The apparent affinity of the interaction between [E1]gp120[/E1] and [E2]CCR-5[/E2] was dramatically lower in the absence of soluble CD4.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp120", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1564_AIMed.d184.s1564.p1", "text": "The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4.", "text_with_entity_marker": "The apparent affinity of the interaction between [E1]gp120[/E1] and CCR-5 was dramatically lower in the absence of soluble [E2]CD4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[49, 54]], "entity_1_idx_in_text_with_entity_marker": [53, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1564_AIMed.d184.s1564.p2", "text": "The apparent affinity of the interaction between gp120 and CCR-5 was dramatically lower in the absence of soluble CD4.", "text_with_entity_marker": "The apparent affinity of the interaction between gp120 and [E1]CCR-5[/E1] was dramatically lower in the absence of soluble [E2]CD4[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CCR-5", "entity_1_idx": [[59, 64]], "entity_1_idx_in_text_with_entity_marker": [63, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1565_AIMed.d184.s1565.p0", "text": "Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed.", "text_with_entity_marker": "Additionally, in the absence of [E1]gp120[/E1], an interaction between a two-domain [E2]CD4[/E2] fragment and CCR-5 was observed.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[75, 78]], "entity_2_idx_in_text_with_entity_marker": [88, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1565_AIMed.d184.s1565.p1", "text": "Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed.", "text_with_entity_marker": "Additionally, in the absence of [E1]gp120[/E1], an interaction between a two-domain CD4 fragment and [E2]CCR-5[/E2] was observed.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1565_AIMed.d184.s1565.p2", "text": "Additionally, in the absence of gp120, an interaction between a two-domain CD4 fragment and CCR-5 was observed.", "text_with_entity_marker": "Additionally, in the absence of gp120, an interaction between a two-domain [E1]CD4[/E1] fragment and [E2]CCR-5[/E2] was observed.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD4", "entity_1_idx": [[75, 78]], "entity_1_idx_in_text_with_entity_marker": [79, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1566_AIMed.d184.s1566.p0", "text": "A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "text_with_entity_marker": "A [E1]gp120[/E1] fragment retaining the [E2]CD4[/E2]-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp120", "entity_1_idx": [[2, 7]], "entity_1_idx_in_text_with_entity_marker": [6, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[31, 34]], "entity_2_idx_in_text_with_entity_marker": [44, 47], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1566_AIMed.d184.s1566.p1", "text": "A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "text_with_entity_marker": "A [E1]gp120[/E1] fragment retaining the CD4-binding site and overlapping epitopes was able to interact with [E2]CCR-5[/E2] only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp120", "entity_1_idx": [[2, 7]], "entity_1_idx_in_text_with_entity_marker": [6, 11], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1566_AIMed.d184.s1566.p2", "text": "A gp120 fragment retaining the CD4-binding site and overlapping epitopes was able to interact with CCR-5 only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "text_with_entity_marker": "A gp120 fragment retaining the [E1]CD4[/E1]-binding site and overlapping epitopes was able to interact with [E2]CCR-5[/E2] only if the V3 loop, which can specify HIV-1 tropism and chemokine receptor choice, was also present on the molecule.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[99, 104]], "entity_2_idx_in_text_with_entity_marker": [112, 117], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p0", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either [E1]CD4[/E1]-induced or V3 epitopes on [E2]gp120[/E2] blocked the interaction of gp12O-CD4 complexes with CCR-5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp120", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p1", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either [E1]CD4[/E1]-induced or V3 epitopes on gp120 blocked the interaction of [E2]gp12O[/E2]-CD4 complexes with CCR-5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp12O", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p2", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either [E1]CD4[/E1]-induced or V3 epitopes on gp120 blocked the interaction of gp12O-[E2]CD4[/E2] complexes with CCR-5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p3", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either [E1]CD4[/E1]-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with [E2]CCR-5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[48, 51]], "entity_1_idx_in_text_with_entity_marker": [52, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p4", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on [E1]gp120[/E1] blocked the interaction of [E2]gp12O[/E2]-CD4 complexes with CCR-5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[78, 83]], "entity_1_idx_in_text_with_entity_marker": [82, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp12O", "entity_2_idx": [[111, 116]], "entity_2_idx_in_text_with_entity_marker": [124, 129], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p5", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on [E1]gp120[/E1] blocked the interaction of gp12O-[E2]CD4[/E2] complexes with CCR-5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[78, 83]], "entity_1_idx_in_text_with_entity_marker": [82, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p6", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on [E1]gp120[/E1] blocked the interaction of gp12O-CD4 complexes with [E2]CCR-5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp120", "entity_1_idx": [[78, 83]], "entity_1_idx_in_text_with_entity_marker": [82, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p7", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of [E1]gp12O[/E1]-[E2]CD4[/E2] complexes with CCR-5.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp12O", "entity_1_idx": [[111, 116]], "entity_1_idx_in_text_with_entity_marker": [115, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p8", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of [E1]gp12O[/E1]-CD4 complexes with [E2]CCR-5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp12O", "entity_1_idx": [[111, 116]], "entity_1_idx_in_text_with_entity_marker": [115, 120], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1567_AIMed.d184.s1567.p9", "text": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-CD4 complexes with CCR-5.", "text_with_entity_marker": "Neutralizing antibodies directed against either CD4-induced or V3 epitopes on gp120 blocked the interaction of gp12O-[E1]CD4[/E1] complexes with [E2]CCR-5[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD4", "entity_1_idx": [[117, 120]], "entity_1_idx_in_text_with_entity_marker": [121, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1568_AIMed.d184.s1568.p0", "text": "These results suggest that HIV-1 attachment to CD4 creates a high-affinity binding site for CCR-5, leading to membrane fusion and virus entry.", "text_with_entity_marker": "These results suggest that HIV-1 attachment to [E1]CD4[/E1] creates a high-affinity binding site for [E2]CCR-5[/E2], leading to membrane fusion and virus entry.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD4", "entity_1_idx": [[47, 50]], "entity_1_idx_in_text_with_entity_marker": [51, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CCR-5", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s909_AIMed.d108.s909.p0", "text": "p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.", "text_with_entity_marker": "[E1]p53[/E1] transcriptional activation mediated by coactivators [E2]TAFII40[/E2] and TAFII60.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[56, 63]], "entity_2_idx_in_text_with_entity_marker": [69, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s909_AIMed.d108.s909.p1", "text": "p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.", "text_with_entity_marker": "[E1]p53[/E1] transcriptional activation mediated by coactivators TAFII40 and [E2]TAFII60[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[68, 75]], "entity_2_idx_in_text_with_entity_marker": [81, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s909_AIMed.d108.s909.p2", "text": "p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60.", "text_with_entity_marker": "p53 transcriptional activation mediated by coactivators [E1]TAFII40[/E1] and [E2]TAFII60[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[56, 63]], "entity_1_idx_in_text_with_entity_marker": [60, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[68, 75]], "entity_2_idx_in_text_with_entity_marker": [81, 88], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s911_AIMed.d108.s911.p0", "text": "The multisubunit transcription factor IID (TFIID) is thought to be a primary target for site-specific activators of transcription.", "text_with_entity_marker": "The multisubunit [E1]transcription factor IID[/E1] ([E2]TFIID[/E2]) is thought to be a primary target for site-specific activators of transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transcription factor IID", "entity_1_idx": [[17, 41]], "entity_1_idx_in_text_with_entity_marker": [21, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[43, 48]], "entity_2_idx_in_text_with_entity_marker": [56, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s912_AIMed.d108.s912.p0", "text": "Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.", "text_with_entity_marker": "Here, a direct interaction between the activation domain of [E1]p53[/E1] and two subunits of the [E2]TFIID[/E2] complex, TAFII40 and TAFII60, is reported.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p53", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIID", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s912_AIMed.d108.s912.p1", "text": "Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.", "text_with_entity_marker": "Here, a direct interaction between the activation domain of [E1]p53[/E1] and two subunits of the TFIID complex, [E2]TAFII40[/E2] and TAFII60, is reported.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[103, 110]], "entity_2_idx_in_text_with_entity_marker": [116, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s912_AIMed.d108.s912.p2", "text": "Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.", "text_with_entity_marker": "Here, a direct interaction between the activation domain of [E1]p53[/E1] and two subunits of the TFIID complex, TAFII40 and [E2]TAFII60[/E2], is reported.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[115, 122]], "entity_2_idx_in_text_with_entity_marker": [128, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s912_AIMed.d108.s912.p3", "text": "Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.", "text_with_entity_marker": "Here, a direct interaction between the activation domain of p53 and two subunits of the [E1]TFIID[/E1] complex, [E2]TAFII40[/E2] and TAFII60, is reported.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[103, 110]], "entity_2_idx_in_text_with_entity_marker": [116, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s912_AIMed.d108.s912.p4", "text": "Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.", "text_with_entity_marker": "Here, a direct interaction between the activation domain of p53 and two subunits of the [E1]TFIID[/E1] complex, TAFII40 and [E2]TAFII60[/E2], is reported.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[115, 122]], "entity_2_idx_in_text_with_entity_marker": [128, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s912_AIMed.d108.s912.p5", "text": "Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAFII40 and TAFII60, is reported.", "text_with_entity_marker": "Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, [E1]TAFII40[/E1] and [E2]TAFII60[/E2], is reported.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[103, 110]], "entity_1_idx_in_text_with_entity_marker": [107, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[115, 122]], "entity_2_idx_in_text_with_entity_marker": [128, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s913_AIMed.d108.s913.p0", "text": "A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAFII40 and TAFII60.", "text_with_entity_marker": "A double point mutation in the activation domain of [E1]p53[/E1] impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both [E2]TAFII40[/E2] and TAFII60.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[173, 180]], "entity_2_idx_in_text_with_entity_marker": [186, 193], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s913_AIMed.d108.s913.p1", "text": "A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAFII40 and TAFII60.", "text_with_entity_marker": "A double point mutation in the activation domain of [E1]p53[/E1] impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAFII40 and [E2]TAFII60[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[52, 55]], "entity_1_idx_in_text_with_entity_marker": [56, 59], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[185, 192]], "entity_2_idx_in_text_with_entity_marker": [198, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s913_AIMed.d108.s913.p2", "text": "A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAFII40 and TAFII60.", "text_with_entity_marker": "A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both [E1]TAFII40[/E1] and [E2]TAFII60[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[173, 180]], "entity_1_idx_in_text_with_entity_marker": [177, 184], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[185, 192]], "entity_2_idx_in_text_with_entity_marker": [198, 205], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p0", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila [E2]TATA binding protein[/E2] (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA binding protein", "entity_2_idx": [[59, 79]], "entity_2_idx_in_text_with_entity_marker": [72, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p1", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila TATA binding protein ([E2]dTBP[/E2]), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTBP", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p2", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila TATA binding protein (dTBP), human [E2]TAFII250[/E2], dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p3", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila TATA binding protein (dTBP), human TAFII250, [E2]dTAFII60[/E2], and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII60", "entity_2_idx": [[104, 112]], "entity_2_idx_in_text_with_entity_marker": [117, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p4", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and [E2]dTAFII40[/E2] supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII40", "entity_2_idx": [[118, 126]], "entity_2_idx_in_text_with_entity_marker": [131, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p5", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas [E2]TBP[/E2] or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[195, 198]], "entity_2_idx_in_text_with_entity_marker": [208, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p6", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking [E2]TAFII40[/E2] and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p7", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial [E1]TFIID[/E1] complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p8", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila [E1]TATA binding protein[/E1] ([E2]dTBP[/E2]), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[59, 79]], "entity_1_idx_in_text_with_entity_marker": [63, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTBP", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p9", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila [E1]TATA binding protein[/E1] (dTBP), human [E2]TAFII250[/E2], dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[59, 79]], "entity_1_idx_in_text_with_entity_marker": [63, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p10", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila [E1]TATA binding protein[/E1] (dTBP), human TAFII250, [E2]dTAFII60[/E2], and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[59, 79]], "entity_1_idx_in_text_with_entity_marker": [63, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII60", "entity_2_idx": [[104, 112]], "entity_2_idx_in_text_with_entity_marker": [117, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p11", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila [E1]TATA binding protein[/E1] (dTBP), human TAFII250, dTAFII60, and [E2]dTAFII40[/E2] supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[59, 79]], "entity_1_idx_in_text_with_entity_marker": [63, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII40", "entity_2_idx": [[118, 126]], "entity_2_idx_in_text_with_entity_marker": [131, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p12", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila [E1]TATA binding protein[/E1] (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas [E2]TBP[/E2] or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[59, 79]], "entity_1_idx_in_text_with_entity_marker": [63, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[195, 198]], "entity_2_idx_in_text_with_entity_marker": [208, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p13", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila [E1]TATA binding protein[/E1] (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking [E2]TAFII40[/E2] and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[59, 79]], "entity_1_idx_in_text_with_entity_marker": [63, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p14", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila [E1]TATA binding protein[/E1] (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TATA binding protein", "entity_1_idx": [[59, 79]], "entity_1_idx_in_text_with_entity_marker": [63, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p15", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein ([E1]dTBP[/E1]), human [E2]TAFII250[/E2], dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTBP", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII250", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p16", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein ([E1]dTBP[/E1]), human TAFII250, [E2]dTAFII60[/E2], and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTBP", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII60", "entity_2_idx": [[104, 112]], "entity_2_idx_in_text_with_entity_marker": [117, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p17", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein ([E1]dTBP[/E1]), human TAFII250, dTAFII60, and [E2]dTAFII40[/E2] supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTBP", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII40", "entity_2_idx": [[118, 126]], "entity_2_idx_in_text_with_entity_marker": [131, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p18", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein ([E1]dTBP[/E1]), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas [E2]TBP[/E2] or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTBP", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[195, 198]], "entity_2_idx_in_text_with_entity_marker": [208, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p19", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein ([E1]dTBP[/E1]), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking [E2]TAFII40[/E2] and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTBP", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p20", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein ([E1]dTBP[/E1]), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTBP", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p21", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human [E1]TAFII250[/E1], [E2]dTAFII60[/E2], and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII250", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII60", "entity_2_idx": [[104, 112]], "entity_2_idx_in_text_with_entity_marker": [117, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p22", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human [E1]TAFII250[/E1], dTAFII60, and [E2]dTAFII40[/E2] supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII250", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII40", "entity_2_idx": [[118, 126]], "entity_2_idx_in_text_with_entity_marker": [131, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p23", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human [E1]TAFII250[/E1], dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas [E2]TBP[/E2] or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII250", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[195, 198]], "entity_2_idx_in_text_with_entity_marker": [208, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p24", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human [E1]TAFII250[/E1], dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking [E2]TAFII40[/E2] and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII250", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p25", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human [E1]TAFII250[/E1], dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII250", "entity_1_idx": [[94, 102]], "entity_1_idx_in_text_with_entity_marker": [98, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p26", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, [E1]dTAFII60[/E1], and [E2]dTAFII40[/E2] supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTAFII60", "entity_1_idx": [[104, 112]], "entity_1_idx_in_text_with_entity_marker": [108, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dTAFII40", "entity_2_idx": [[118, 126]], "entity_2_idx_in_text_with_entity_marker": [131, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p27", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, [E1]dTAFII60[/E1], and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas [E2]TBP[/E2] or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTAFII60", "entity_1_idx": [[104, 112]], "entity_1_idx_in_text_with_entity_marker": [108, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[195, 198]], "entity_2_idx_in_text_with_entity_marker": [208, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p28", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, [E1]dTAFII60[/E1], and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking [E2]TAFII40[/E2] and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTAFII60", "entity_1_idx": [[104, 112]], "entity_1_idx_in_text_with_entity_marker": [108, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p29", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, [E1]dTAFII60[/E1], and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTAFII60", "entity_1_idx": [[104, 112]], "entity_1_idx_in_text_with_entity_marker": [108, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p30", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and [E1]dTAFII40[/E1] supported activation by a Gal4-p53 fusion protein in vitro, whereas [E2]TBP[/E2] or a subcomplex lacking TAFII40 and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTAFII40", "entity_1_idx": [[118, 126]], "entity_1_idx_in_text_with_entity_marker": [122, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[195, 198]], "entity_2_idx_in_text_with_entity_marker": [208, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p31", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and [E1]dTAFII40[/E1] supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking [E2]TAFII40[/E2] and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTAFII40", "entity_1_idx": [[118, 126]], "entity_1_idx_in_text_with_entity_marker": [122, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p32", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and [E1]dTAFII40[/E1] supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dTAFII40", "entity_1_idx": [[118, 126]], "entity_1_idx_in_text_with_entity_marker": [122, 130], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p33", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas [E1]TBP[/E1] or a subcomplex lacking [E2]TAFII40[/E2] and TAFII60 did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[195, 198]], "entity_1_idx_in_text_with_entity_marker": [199, 202], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII40", "entity_2_idx": [[223, 230]], "entity_2_idx_in_text_with_entity_marker": [236, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p34", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas [E1]TBP[/E1] or a subcomplex lacking TAFII40 and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[195, 198]], "entity_1_idx_in_text_with_entity_marker": [199, 202], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s914_AIMed.d108.s914.p35", "text": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAFII40 and TAFII60 did not.", "text_with_entity_marker": "Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAFII250, dTAFII60, and dTAFII40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking [E1]TAFII40[/E1] and [E2]TAFII60[/E2] did not.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[223, 230]], "entity_1_idx_in_text_with_entity_marker": [227, 234], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[235, 242]], "entity_2_idx_in_text_with_entity_marker": [248, 255], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s915_AIMed.d108.s915.p0", "text": "Together, these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex.", "text_with_entity_marker": "Together, these results suggest that [E1]TAFII40[/E1] and [E2]TAFII60[/E2] are important targets for transmitting activation signals between p53 and the initiation complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TAFII40", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TAFII60", "entity_2_idx": [[49, 56]], "entity_2_idx_in_text_with_entity_marker": [62, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s915_AIMed.d108.s915.p1", "text": "Together, these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex.", "text_with_entity_marker": "Together, these results suggest that [E1]TAFII40[/E1] and TAFII60 are important targets for transmitting activation signals between [E2]p53[/E2] and the initiation complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII40", "entity_1_idx": [[37, 44]], "entity_1_idx_in_text_with_entity_marker": [41, 48], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d108.s915_AIMed.d108.s915.p2", "text": "Together, these results suggest that TAFII40 and TAFII60 are important targets for transmitting activation signals between p53 and the initiation complex.", "text_with_entity_marker": "Together, these results suggest that TAFII40 and [E1]TAFII60[/E1] are important targets for transmitting activation signals between [E2]p53[/E2] and the initiation complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TAFII60", "entity_1_idx": [[49, 56]], "entity_1_idx_in_text_with_entity_marker": [53, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s525_AIMed.d60.s525.p0", "text": "Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.", "text_with_entity_marker": "Activation of [E1-E2]mitogen-activated protein kinase[/E1] kinase[/E2] by v-Raf in NIH 3T3 cells and in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mitogen-activated protein kinase", "entity_1_idx": [[14, 46]], "entity_1_idx_in_text_with_entity_marker": [21, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase[/E1] kinase", "entity_2_idx": [[14, 53]], "entity_2_idx_in_text_with_entity_marker": [21, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s525_AIMed.d60.s525.p1", "text": "Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.", "text_with_entity_marker": "Activation of [E1]mitogen-activated protein kinase[/E1] kinase by [E2]v-Raf[/E2] in NIH 3T3 cells and in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "mitogen-activated protein kinase", "entity_1_idx": [[14, 46]], "entity_1_idx_in_text_with_entity_marker": [18, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "v-Raf", "entity_2_idx": [[57, 62]], "entity_2_idx_in_text_with_entity_marker": [70, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s525_AIMed.d60.s525.p2", "text": "Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.", "text_with_entity_marker": "Activation of [E1]mitogen-activated protein kinase kinase[/E1] by [E2]v-Raf[/E2] in NIH 3T3 cells and in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "mitogen-activated protein kinase kinase", "entity_1_idx": [[14, 53]], "entity_1_idx_in_text_with_entity_marker": [18, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "v-Raf", "entity_2_idx": [[57, 62]], "entity_2_idx_in_text_with_entity_marker": [70, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s527_AIMed.d60.s527.p0", "text": "MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "text_with_entity_marker": "[E1]MAP kinase[/E1] and the protein kinase that activates it ([E2]MAP kinase kinase[/E2]) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MAP kinase", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[53, 70]], "entity_2_idx_in_text_with_entity_marker": [66, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s527_AIMed.d60.s527.p1", "text": "MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "text_with_entity_marker": "[E1]MAP kinase[/E1] and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the [E2]c-Raf-1[/E2] protein kinase.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MAP kinase", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Raf-1", "entity_2_idx": [[207, 214]], "entity_2_idx_in_text_with_entity_marker": [220, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s527_AIMed.d60.s527.p2", "text": "MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "text_with_entity_marker": "MAP kinase and the protein kinase that activates it ([E1]MAP kinase kinase[/E1]) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the [E2]c-Raf-1[/E2] protein kinase.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MAP kinase kinase", "entity_1_idx": [[53, 70]], "entity_1_idx_in_text_with_entity_marker": [57, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Raf-1", "entity_2_idx": [[207, 214]], "entity_2_idx_in_text_with_entity_marker": [220, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s528_AIMed.d60.s528.p0", "text": "The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro.", "text_with_entity_marker": "The [E1]v-Raf[/E1] proteins purified from cells infected with EC12 or 22W viruses activated [E2]MAP kinase[/E2] kinase from skeletal muscle in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "v-Raf", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[83, 93]], "entity_2_idx_in_text_with_entity_marker": [96, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s528_AIMed.d60.s528.p1", "text": "The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro.", "text_with_entity_marker": "The [E1]v-Raf[/E1] proteins purified from cells infected with EC12 or 22W viruses activated [E2]MAP kinase kinase[/E2] from skeletal muscle in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "v-Raf", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[83, 100]], "entity_2_idx_in_text_with_entity_marker": [96, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s528_AIMed.d60.s528.p2", "text": "The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro.", "text_with_entity_marker": "The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated [E1-E2]MAP kinase[/E1] kinase[/E2] from skeletal muscle in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MAP kinase", "entity_1_idx": [[83, 93]], "entity_1_idx_in_text_with_entity_marker": [90, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase[/E1] kinase", "entity_2_idx": [[83, 100]], "entity_2_idx_in_text_with_entity_marker": [90, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s529_AIMed.d60.s529.p0", "text": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.", "text_with_entity_marker": "Furthermore, a bacterially expressed [E1]v-Raf[/E1] fusion protein (glutathione S-transferase-p3722W) also activated [E2]MAP kinase[/E2] kinase in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "v-Raf", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[108, 118]], "entity_2_idx_in_text_with_entity_marker": [121, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s529_AIMed.d60.s529.p1", "text": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.", "text_with_entity_marker": "Furthermore, a bacterially expressed [E1]v-Raf[/E1] fusion protein (glutathione S-transferase-p3722W) also activated [E2]MAP kinase kinase[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "v-Raf", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[108, 125]], "entity_2_idx_in_text_with_entity_marker": [121, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s529_AIMed.d60.s529.p2", "text": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.", "text_with_entity_marker": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated [E1-E2]MAP kinase[/E1] kinase[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MAP kinase", "entity_1_idx": [[108, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase[/E1] kinase", "entity_2_idx": [[108, 125]], "entity_2_idx_in_text_with_entity_marker": [115, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s530_AIMed.d60.s530.p0", "text": "These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.", "text_with_entity_marker": "These findings suggest that one function of [E1]c-Raf-1[/E1] in mitogenic signaling is to phosphorylate and activate [E2]MAP kinase[/E2] kinase.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Raf-1", "entity_1_idx": [[44, 51]], "entity_1_idx_in_text_with_entity_marker": [48, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[108, 118]], "entity_2_idx_in_text_with_entity_marker": [121, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s530_AIMed.d60.s530.p1", "text": "These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.", "text_with_entity_marker": "These findings suggest that one function of [E1]c-Raf-1[/E1] in mitogenic signaling is to phosphorylate and activate [E2]MAP kinase kinase[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Raf-1", "entity_1_idx": [[44, 51]], "entity_1_idx_in_text_with_entity_marker": [48, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[108, 125]], "entity_2_idx_in_text_with_entity_marker": [121, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s530_AIMed.d60.s530.p2", "text": "These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.", "text_with_entity_marker": "These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate [E1-E2]MAP kinase[/E1] kinase[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MAP kinase", "entity_1_idx": [[108, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase[/E1] kinase", "entity_2_idx": [[108, 125]], "entity_2_idx_in_text_with_entity_marker": [115, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1727_AIMed.d201.s1727.p0", "text": "Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.", "text_with_entity_marker": "[E1]Hepatitis B virus X protein[/E1] is a transcriptional modulator that communicates with [E2]transcription factor IIB[/E2] and the RNA polymerase II subunit 5.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hepatitis B virus X protein", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transcription factor IIB", "entity_2_idx": [[82, 106]], "entity_2_idx_in_text_with_entity_marker": [95, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1727_AIMed.d201.s1727.p1", "text": "Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.", "text_with_entity_marker": "[E1]Hepatitis B virus X protein[/E1] is a transcriptional modulator that communicates with transcription factor IIB and the [E2]RNA polymerase II subunit 5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hepatitis B virus X protein", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RNA polymerase II subunit 5", "entity_2_idx": [[115, 142]], "entity_2_idx_in_text_with_entity_marker": [128, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1727_AIMed.d201.s1727.p2", "text": "Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.", "text_with_entity_marker": "Hepatitis B virus X protein is a transcriptional modulator that communicates with [E1]transcription factor IIB[/E1] and the [E2]RNA polymerase II subunit 5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transcription factor IIB", "entity_1_idx": [[82, 106]], "entity_1_idx_in_text_with_entity_marker": [86, 110], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RNA polymerase II subunit 5", "entity_2_idx": [[115, 142]], "entity_2_idx_in_text_with_entity_marker": [128, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1728_AIMed.d201.s1728.p0", "text": "Hepatitis B virus X protein (HBx) transactivates viral and cellular genes through a wide variety of cis-elements.", "text_with_entity_marker": "[E1]Hepatitis B virus X protein[/E1] ([E2]HBx[/E2]) transactivates viral and cellular genes through a wide variety of cis-elements.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hepatitis B virus X protein", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[29, 32]], "entity_2_idx_in_text_with_entity_marker": [42, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1730_AIMed.d201.s1730.p0", "text": "Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "text_with_entity_marker": "Our finding that [E1]HBx[/E1] directly interacts with [E2]RNA polymerase II subunit 5[/E2] (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HBx", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RNA polymerase II subunit 5", "entity_2_idx": [[45, 72]], "entity_2_idx_in_text_with_entity_marker": [58, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1730_AIMed.d201.s1730.p1", "text": "Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "text_with_entity_marker": "Our finding that [E1]HBx[/E1] directly interacts with RNA polymerase II subunit 5 ([E2]RPB5[/E2]), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HBx", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[74, 78]], "entity_2_idx_in_text_with_entity_marker": [87, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1730_AIMed.d201.s1730.p2", "text": "Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "text_with_entity_marker": "Our finding that [E1]HBx[/E1] directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that [E2]HBx[/E2] directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[17, 20]], "entity_1_idx_in_text_with_entity_marker": [21, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1730_AIMed.d201.s1730.p3", "text": "Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "text_with_entity_marker": "Our finding that HBx directly interacts with [E1]RNA polymerase II subunit 5[/E1] ([E2]RPB5[/E2]), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RNA polymerase II subunit 5", "entity_1_idx": [[45, 72]], "entity_1_idx_in_text_with_entity_marker": [49, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[74, 78]], "entity_2_idx_in_text_with_entity_marker": [87, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1730_AIMed.d201.s1730.p4", "text": "Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "text_with_entity_marker": "Our finding that HBx directly interacts with [E1]RNA polymerase II subunit 5[/E1] (RPB5), a common subunit of RNA polymerases, implies that [E2]HBx[/E2] directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RNA polymerase II subunit 5", "entity_1_idx": [[45, 72]], "entity_1_idx_in_text_with_entity_marker": [49, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1730_AIMed.d201.s1730.p5", "text": "Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "text_with_entity_marker": "Our finding that HBx directly interacts with RNA polymerase II subunit 5 ([E1]RPB5[/E1]), a common subunit of RNA polymerases, implies that [E2]HBx[/E2] directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[74, 78]], "entity_1_idx_in_text_with_entity_marker": [78, 82], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[131, 134]], "entity_2_idx_in_text_with_entity_marker": [144, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1731_AIMed.d201.s1731.p0", "text": "In this context, we examined the possibility that HBx and RPB5 interact with other general transcription factors.", "text_with_entity_marker": "In this context, we examined the possibility that [E1]HBx[/E1] and [E2]RPB5[/E2] interact with other general transcription factors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1732_AIMed.d201.s1732.p0", "text": "HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "text_with_entity_marker": "[E1]HBx[/E1] and [E2]RPB5[/E2] specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[8, 12]], "entity_2_idx_in_text_with_entity_marker": [21, 25], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1732_AIMed.d201.s1732.p1", "text": "HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "text_with_entity_marker": "[E1]HBx[/E1] and RPB5 specifically bound to [E2]transcription factor IIB[/E2] (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transcription factor IIB", "entity_2_idx": [[35, 59]], "entity_2_idx_in_text_with_entity_marker": [48, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1732_AIMed.d201.s1732.p2", "text": "HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "text_with_entity_marker": "[E1]HBx[/E1] and RPB5 specifically bound to transcription factor IIB ([E2]TFIIB[/E2]) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[61, 66]], "entity_2_idx_in_text_with_entity_marker": [74, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1732_AIMed.d201.s1732.p3", "text": "HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "text_with_entity_marker": "HBx and [E1]RPB5[/E1] specifically bound to [E2]transcription factor IIB[/E2] (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[8, 12]], "entity_1_idx_in_text_with_entity_marker": [12, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transcription factor IIB", "entity_2_idx": [[35, 59]], "entity_2_idx_in_text_with_entity_marker": [48, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1732_AIMed.d201.s1732.p4", "text": "HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "text_with_entity_marker": "HBx and [E1]RPB5[/E1] specifically bound to transcription factor IIB ([E2]TFIIB[/E2]) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[8, 12]], "entity_1_idx_in_text_with_entity_marker": [12, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[61, 66]], "entity_2_idx_in_text_with_entity_marker": [74, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1732_AIMed.d201.s1732.p5", "text": "HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "text_with_entity_marker": "HBx and RPB5 specifically bound to [E1]transcription factor IIB[/E1] ([E2]TFIIB[/E2]) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "transcription factor IIB", "entity_1_idx": [[35, 59]], "entity_1_idx_in_text_with_entity_marker": [39, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[61, 66]], "entity_2_idx_in_text_with_entity_marker": [74, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1733_AIMed.d201.s1733.p0", "text": "Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.", "text_with_entity_marker": "Delineation of the binding regions of these three proteins revealed that [E1]HBx[/E1], [E2]RPB5[/E2], and TFIIB each has two binding regions for the other two proteins.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HBx", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[78, 82]], "entity_2_idx_in_text_with_entity_marker": [91, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1733_AIMed.d201.s1733.p1", "text": "Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.", "text_with_entity_marker": "Delineation of the binding regions of these three proteins revealed that [E1]HBx[/E1], RPB5, and [E2]TFIIB[/E2] each has two binding regions for the other two proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[73, 76]], "entity_1_idx_in_text_with_entity_marker": [77, 80], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1733_AIMed.d201.s1733.p2", "text": "Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.", "text_with_entity_marker": "Delineation of the binding regions of these three proteins revealed that HBx, [E1]RPB5[/E1], and [E2]TFIIB[/E2] each has two binding regions for the other two proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[78, 82]], "entity_1_idx_in_text_with_entity_marker": [82, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p0", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some [E1]HBx[/E1] substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either [E2]TFIIB[/E2] or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[128, 133]], "entity_2_idx_in_text_with_entity_marker": [141, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p1", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some [E1]HBx[/E1] substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or [E2]RPB5[/E2] in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HBx", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[137, 141]], "entity_2_idx_in_text_with_entity_marker": [150, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p2", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some [E1]HBx[/E1] substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that [E2]HBx[/E2] transactivation requires the interactions of both RPB5 and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[190, 193]], "entity_2_idx_in_text_with_entity_marker": [203, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p3", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some [E1]HBx[/E1] substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both [E2]RPB5[/E2] and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p4", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some [E1]HBx[/E1] substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[5, 8]], "entity_1_idx_in_text_with_entity_marker": [9, 12], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[253, 258]], "entity_2_idx_in_text_with_entity_marker": [266, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p5", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either [E1]TFIIB[/E1] or [E2]RPB5[/E2] in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[137, 141]], "entity_2_idx_in_text_with_entity_marker": [150, 154], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p6", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either [E1]TFIIB[/E1] or RPB5 in a mutually exclusive manner, suggesting that [E2]HBx[/E2] transactivation requires the interactions of both RPB5 and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[190, 193]], "entity_2_idx_in_text_with_entity_marker": [203, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p7", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either [E1]TFIIB[/E1] or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both [E2]RPB5[/E2] and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p8", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either [E1]TFIIB[/E1] or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[128, 133]], "entity_1_idx_in_text_with_entity_marker": [132, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[253, 258]], "entity_2_idx_in_text_with_entity_marker": [266, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p9", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or [E1]RPB5[/E1] in a mutually exclusive manner, suggesting that [E2]HBx[/E2] transactivation requires the interactions of both RPB5 and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[137, 141]], "entity_1_idx_in_text_with_entity_marker": [141, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HBx", "entity_2_idx": [[190, 193]], "entity_2_idx_in_text_with_entity_marker": [203, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p10", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or [E1]RPB5[/E1] in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both [E2]RPB5[/E2] and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[137, 141]], "entity_1_idx_in_text_with_entity_marker": [141, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p11", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or [E1]RPB5[/E1] in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[137, 141]], "entity_1_idx_in_text_with_entity_marker": [141, 145], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[253, 258]], "entity_2_idx_in_text_with_entity_marker": [266, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p12", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that [E1]HBx[/E1] transactivation requires the interactions of both [E2]RPB5[/E2] and TFIIB.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "HBx", "entity_1_idx": [[190, 193]], "entity_1_idx_in_text_with_entity_marker": [194, 197], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p13", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that [E1]HBx[/E1] transactivation requires the interactions of both RPB5 and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[190, 193]], "entity_1_idx_in_text_with_entity_marker": [194, 197], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[253, 258]], "entity_2_idx_in_text_with_entity_marker": [266, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1735_AIMed.d201.s1735.p14", "text": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.", "text_with_entity_marker": "Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both [E1]RPB5[/E1] and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[244, 248]], "entity_1_idx_in_text_with_entity_marker": [248, 252], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[253, 258]], "entity_2_idx_in_text_with_entity_marker": [266, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1736_AIMed.d201.s1736.p0", "text": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.", "text_with_entity_marker": "These results indicated that [E1]HBx[/E1] is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and [E2]TFIIB[/E2] through communication with RPB5 and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1736_AIMed.d201.s1736.p1", "text": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.", "text_with_entity_marker": "These results indicated that [E1]HBx[/E1] is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with [E2]RPB5[/E2] and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1736_AIMed.d201.s1736.p2", "text": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.", "text_with_entity_marker": "These results indicated that [E1]HBx[/E1] is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HBx", "entity_1_idx": [[29, 32]], "entity_1_idx_in_text_with_entity_marker": [33, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[204, 209]], "entity_2_idx_in_text_with_entity_marker": [217, 222], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1736_AIMed.d201.s1736.p3", "text": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.", "text_with_entity_marker": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and [E1]TFIIB[/E1] through communication with [E2]RPB5[/E2] and TFIIB.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RPB5", "entity_2_idx": [[195, 199]], "entity_2_idx_in_text_with_entity_marker": [208, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1736_AIMed.d201.s1736.p4", "text": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.", "text_with_entity_marker": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and [E1]TFIIB[/E1] through communication with RPB5 and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[162, 167]], "entity_1_idx_in_text_with_entity_marker": [166, 171], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[204, 209]], "entity_2_idx_in_text_with_entity_marker": [217, 222], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d201.s1736_AIMed.d201.s1736.p5", "text": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.", "text_with_entity_marker": "These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with [E1]RPB5[/E1] and [E2]TFIIB[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RPB5", "entity_1_idx": [[195, 199]], "entity_1_idx_in_text_with_entity_marker": [199, 203], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[204, 209]], "entity_2_idx_in_text_with_entity_marker": [217, 222], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1928_AIMed.d222.s1928.p0", "text": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "text_with_entity_marker": "The protein product of [E1]c-cbl[/E1] proto-oncogene is known to interact with several proteins, including [E2]Grb2[/E2], Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-cbl", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Grb2", "entity_2_idx": [[98, 102]], "entity_2_idx_in_text_with_entity_marker": [111, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1928_AIMed.d222.s1928.p1", "text": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "text_with_entity_marker": "The protein product of [E1]c-cbl[/E1] proto-oncogene is known to interact with several proteins, including Grb2, [E2]Crk[/E2] and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-cbl", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1928_AIMed.d222.s1928.p2", "text": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "text_with_entity_marker": "The protein product of [E1]c-cbl[/E1] proto-oncogene is known to interact with several proteins, including Grb2, Crk and [E2]PI3 kinase[/E2], and is thought to regulate signalling by many cell surface receptors.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-cbl", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI3 kinase", "entity_2_idx": [[112, 122]], "entity_2_idx_in_text_with_entity_marker": [125, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1928_AIMed.d222.s1928.p3", "text": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "text_with_entity_marker": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including [E1]Grb2[/E1], [E2]Crk[/E2] and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[98, 102]], "entity_1_idx_in_text_with_entity_marker": [102, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Crk", "entity_2_idx": [[104, 107]], "entity_2_idx_in_text_with_entity_marker": [117, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1928_AIMed.d222.s1928.p4", "text": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "text_with_entity_marker": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including [E1]Grb2[/E1], Crk and [E2]PI3 kinase[/E2], and is thought to regulate signalling by many cell surface receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Grb2", "entity_1_idx": [[98, 102]], "entity_1_idx_in_text_with_entity_marker": [102, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI3 kinase", "entity_2_idx": [[112, 122]], "entity_2_idx_in_text_with_entity_marker": [125, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1928_AIMed.d222.s1928.p5", "text": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.", "text_with_entity_marker": "The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, [E1]Crk[/E1] and [E2]PI3 kinase[/E2], and is thought to regulate signalling by many cell surface receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Crk", "entity_1_idx": [[104, 107]], "entity_1_idx_in_text_with_entity_marker": [108, 111], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PI3 kinase", "entity_2_idx": [[112, 122]], "entity_2_idx_in_text_with_entity_marker": [125, 135], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1929_AIMed.d222.s1929.p0", "text": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.", "text_with_entity_marker": "The precise function of [E1]c-Cbl[/E1] in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that [E2]c-Cbl[/E2] is a negative regulator of the epidermal growth factor receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Cbl", "entity_2_idx": [[130, 135]], "entity_2_idx_in_text_with_entity_marker": [143, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1929_AIMed.d222.s1929.p1", "text": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.", "text_with_entity_marker": "The precise function of [E1]c-Cbl[/E1] in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the [E2]epidermal growth factor[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor", "entity_2_idx": [[167, 190]], "entity_2_idx_in_text_with_entity_marker": [180, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1929_AIMed.d222.s1929.p2", "text": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.", "text_with_entity_marker": "The precise function of [E1]c-Cbl[/E1] in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the [E2]epidermal growth factor receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor receptor", "entity_2_idx": [[167, 199]], "entity_2_idx_in_text_with_entity_marker": [180, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1929_AIMed.d222.s1929.p3", "text": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.", "text_with_entity_marker": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that [E1]c-Cbl[/E1] is a negative regulator of the [E2]epidermal growth factor[/E2] receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Cbl", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor", "entity_2_idx": [[167, 190]], "entity_2_idx_in_text_with_entity_marker": [180, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1929_AIMed.d222.s1929.p4", "text": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.", "text_with_entity_marker": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that [E1]c-Cbl[/E1] is a negative regulator of the [E2]epidermal growth factor receptor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Cbl", "entity_1_idx": [[130, 135]], "entity_1_idx_in_text_with_entity_marker": [134, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor receptor", "entity_2_idx": [[167, 199]], "entity_2_idx_in_text_with_entity_marker": [180, 212], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1929_AIMed.d222.s1929.p5", "text": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the epidermal growth factor receptor.", "text_with_entity_marker": "The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the [E1-E2]epidermal growth factor[/E1] receptor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "epidermal growth factor", "entity_1_idx": [[167, 190]], "entity_1_idx_in_text_with_entity_marker": [174, 197], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "epidermal growth factor[/E1] receptor", "entity_2_idx": [[167, 199]], "entity_2_idx_in_text_with_entity_marker": [174, 211], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1931_AIMed.d222.s1931.p0", "text": "The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.", "text_with_entity_marker": "The screen identified interactions involving [E1]c-Cbl[/E1] and two 14-3-3 isoforms, [E2]cytokeratin 18[/E2], human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Cbl", "entity_1_idx": [[45, 50]], "entity_1_idx_in_text_with_entity_marker": [49, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cytokeratin 18", "entity_2_idx": [[76, 90]], "entity_2_idx_in_text_with_entity_marker": [89, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1931_AIMed.d222.s1931.p1", "text": "The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.", "text_with_entity_marker": "The screen identified interactions involving [E1]c-Cbl[/E1] and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, [E2]SH3 P17[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "c-Cbl", "entity_1_idx": [[45, 50]], "entity_1_idx_in_text_with_entity_marker": [49, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SH3 P17", "entity_2_idx": [[181, 188]], "entity_2_idx_in_text_with_entity_marker": [194, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d222.s1931_AIMed.d222.s1931.p2", "text": "The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.", "text_with_entity_marker": "The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, [E1]cytokeratin 18[/E1], human unconventional myosin IC, and a recently identified SH3 domain containing protein, [E2]SH3 P17[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cytokeratin 18", "entity_1_idx": [[76, 90]], "entity_1_idx_in_text_with_entity_marker": [80, 94], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SH3 P17", "entity_2_idx": [[181, 188]], "entity_2_idx_in_text_with_entity_marker": [194, 201], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1585_AIMed.d187.s1585.p0", "text": "Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation.", "text_with_entity_marker": "Interaction of [E1]transthyretin[/E1] with [E2]amyloid beta-protein[/E2]: binding and inhibition of amyloid formation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "transthyretin", "entity_1_idx": [[15, 28]], "entity_1_idx_in_text_with_entity_marker": [19, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "amyloid beta-protein", "entity_2_idx": [[34, 54]], "entity_2_idx_in_text_with_entity_marker": [47, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1586_AIMed.d187.s1586.p0", "text": "Aggregated amyloid beta-protein (A beta) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease.", "text_with_entity_marker": "Aggregated [E1]amyloid beta-protein[/E1] ([E2]A beta[/E2]) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "amyloid beta-protein", "entity_1_idx": [[11, 31]], "entity_1_idx_in_text_with_entity_marker": [15, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[33, 39]], "entity_2_idx_in_text_with_entity_marker": [46, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1588_AIMed.d187.s1588.p0", "text": "The analysis of complexes of A beta with CSF proteins in a KBr gradient revealed an association of A beta only with free proteins and not with lipoprotein particles.", "text_with_entity_marker": "The analysis of complexes of [E1]A beta[/E1] with CSF proteins in a KBr gradient revealed an association of [E2]A beta[/E2] only with free proteins and not with lipoprotein particles.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "A beta", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[99, 105]], "entity_2_idx_in_text_with_entity_marker": [112, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1589_AIMed.d187.s1589.p0", "text": "Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.", "text_with_entity_marker": "[E1]Transthyretin[/E1] ([E2]TTR[/E2]), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Transthyretin", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[15, 18]], "entity_2_idx_in_text_with_entity_marker": [28, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1589_AIMed.d187.s1589.p1", "text": "Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.", "text_with_entity_marker": "[E1]Transthyretin[/E1] (TTR), a second major CSF protein, formed SDS-stable complexes with [E2]A beta[/E2] and significantly decreased the rate of A beta fibril formation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Transthyretin", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[82, 88]], "entity_2_idx_in_text_with_entity_marker": [95, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1589_AIMed.d187.s1589.p2", "text": "Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.", "text_with_entity_marker": "[E1]Transthyretin[/E1] (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of [E2]A beta[/E2] fibril formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Transthyretin", "entity_1_idx": [[0, 13]], "entity_1_idx_in_text_with_entity_marker": [4, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[129, 135]], "entity_2_idx_in_text_with_entity_marker": [142, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1589_AIMed.d187.s1589.p3", "text": "Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.", "text_with_entity_marker": "Transthyretin ([E1]TTR[/E1]), a second major CSF protein, formed SDS-stable complexes with [E2]A beta[/E2] and significantly decreased the rate of A beta fibril formation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TTR", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[82, 88]], "entity_2_idx_in_text_with_entity_marker": [95, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1589_AIMed.d187.s1589.p4", "text": "Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.", "text_with_entity_marker": "Transthyretin ([E1]TTR[/E1]), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of [E2]A beta[/E2] fibril formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[129, 135]], "entity_2_idx_in_text_with_entity_marker": [142, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1589_AIMed.d187.s1589.p5", "text": "Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.", "text_with_entity_marker": "Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with [E1]A beta[/E1] and significantly decreased the rate of [E2]A beta[/E2] fibril formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "A beta", "entity_1_idx": [[82, 88]], "entity_1_idx_in_text_with_entity_marker": [86, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[129, 135]], "entity_2_idx_in_text_with_entity_marker": [142, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1590_AIMed.d187.s1590.p0", "text": "In physiological buffers and CSF, TTR exclusively decreased the level of A beta pentamers.", "text_with_entity_marker": "In physiological buffers and CSF, [E1]TTR[/E1] exclusively decreased the level of [E2]A beta[/E2] pentamers.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TTR", "entity_1_idx": [[34, 37]], "entity_1_idx_in_text_with_entity_marker": [38, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[73, 79]], "entity_2_idx_in_text_with_entity_marker": [86, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1591_AIMed.d187.s1591.p0", "text": "Endogenous TTR-A beta complexes were detected in human CSF by immunoprecipitation.", "text_with_entity_marker": "Endogenous [E1]TTR[/E1]-[E2]A beta[/E2] complexes were detected in human CSF by immunoprecipitation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TTR", "entity_1_idx": [[11, 14]], "entity_1_idx_in_text_with_entity_marker": [15, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[15, 21]], "entity_2_idx_in_text_with_entity_marker": [28, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1592_AIMed.d187.s1592.p0", "text": "Using site-directed mutagenesis and computer-assisted modelling, we identified amino acid residues on the surface of the TTR monomer that interact with A beta.", "text_with_entity_marker": "Using site-directed mutagenesis and computer-assisted modelling, we identified amino acid residues on the surface of the [E1]TTR[/E1] monomer that interact with [E2]A beta[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TTR", "entity_1_idx": [[121, 124]], "entity_1_idx_in_text_with_entity_marker": [125, 128], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[152, 158]], "entity_2_idx_in_text_with_entity_marker": [165, 171], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1594_AIMed.d187.s1594.p0", "text": "We propose that A beta binding proteins play a key role in the modulation of A beta aggregation and normally prevent amyloid formation in biological fluids and in the brain.", "text_with_entity_marker": "We propose that [E1]A beta[/E1] binding proteins play a key role in the modulation of [E2]A beta[/E2] aggregation and normally prevent amyloid formation in biological fluids and in the brain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "A beta", "entity_1_idx": [[16, 22]], "entity_1_idx_in_text_with_entity_marker": [20, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[77, 83]], "entity_2_idx_in_text_with_entity_marker": [90, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d159.s1340_AIMed.d159.s1340.p0", "text": "The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.", "text_with_entity_marker": "The carboxy-terminal region of [E1]dystrophin[/E1] has previously been shown to interact directly with [E2]alpha1 syntrophin[/E2], a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "dystrophin", "entity_1_idx": [[31, 41]], "entity_1_idx_in_text_with_entity_marker": [35, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha1 syntrophin", "entity_2_idx": [[94, 111]], "entity_2_idx_in_text_with_entity_marker": [107, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d159.s1340_AIMed.d159.s1340.p1", "text": "The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.", "text_with_entity_marker": "The carboxy-terminal region of [E1]dystrophin[/E1] has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the [E2]dystrophin[/E2]-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "dystrophin", "entity_1_idx": [[31, 41]], "entity_1_idx_in_text_with_entity_marker": [35, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[144, 154]], "entity_2_idx_in_text_with_entity_marker": [157, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d159.s1340_AIMed.d159.s1340.p2", "text": "The carboxy-terminal region of dystrophin has previously been shown to interact directly with alpha1 syntrophin, a cytoplasmic component of the dystrophin-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.", "text_with_entity_marker": "The carboxy-terminal region of dystrophin has previously been shown to interact directly with [E1]alpha1 syntrophin[/E1], a cytoplasmic component of the [E2]dystrophin[/E2]-glycoprotein complex, by in vitro biochemical studies such as overlay assay or immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "alpha1 syntrophin", "entity_1_idx": [[94, 111]], "entity_1_idx_in_text_with_entity_marker": [98, 115], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "dystrophin", "entity_2_idx": [[144, 154]], "entity_2_idx_in_text_with_entity_marker": [157, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1262_AIMed.d149.s1262.p0", "text": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.", "text_with_entity_marker": "The SH2/SH3 domain-containing protein [E1]GRB2[/E1] interacts with tyrosine-phosphorylated [E2]IRS1[/E2] and Shc: implications for insulin control of ras signalling.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS1", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1262_AIMed.d149.s1262.p1", "text": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.", "text_with_entity_marker": "The SH2/SH3 domain-containing protein [E1]GRB2[/E1] interacts with tyrosine-phosphorylated IRS1 and [E2]Shc[/E2]: implications for insulin control of ras signalling.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1262_AIMed.d149.s1262.p2", "text": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.", "text_with_entity_marker": "The SH2/SH3 domain-containing protein [E1]GRB2[/E1] interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of [E2]ras[/E2] signalling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ras", "entity_2_idx": [[132, 135]], "entity_2_idx_in_text_with_entity_marker": [145, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1262_AIMed.d149.s1262.p3", "text": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.", "text_with_entity_marker": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated [E1]IRS1[/E1] and [E2]Shc[/E2]: implications for insulin control of ras signalling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS1", "entity_1_idx": [[82, 86]], "entity_1_idx_in_text_with_entity_marker": [86, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1262_AIMed.d149.s1262.p4", "text": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.", "text_with_entity_marker": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated [E1]IRS1[/E1] and Shc: implications for insulin control of [E2]ras[/E2] signalling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS1", "entity_1_idx": [[82, 86]], "entity_1_idx_in_text_with_entity_marker": [86, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ras", "entity_2_idx": [[132, 135]], "entity_2_idx_in_text_with_entity_marker": [145, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1262_AIMed.d149.s1262.p5", "text": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.", "text_with_entity_marker": "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and [E1]Shc[/E1]: implications for insulin control of [E2]ras[/E2] signalling.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Shc", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ras", "entity_2_idx": [[132, 135]], "entity_2_idx_in_text_with_entity_marker": [145, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1263_AIMed.d149.s1263.p0", "text": "GRB2, a small protein comprising one SH2 domain and two SH3 domains, represents the human homologue of the Caenorhabditis elegans protein, sem-5.", "text_with_entity_marker": "[E1]GRB2[/E1], a small protein comprising one SH2 domain and two SH3 domains, represents the human homologue of the Caenorhabditis elegans protein, [E2]sem-5[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sem-5", "entity_2_idx": [[139, 144]], "entity_2_idx_in_text_with_entity_marker": [152, 157], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1264_AIMed.d149.s1264.p0", "text": "Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.", "text_with_entity_marker": "Both [E1]GRB2[/E1] and [E2]sem-5[/E2] have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[5, 9]], "entity_1_idx_in_text_with_entity_marker": [9, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "sem-5", "entity_2_idx": [[14, 19]], "entity_2_idx_in_text_with_entity_marker": [27, 32], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1264_AIMed.d149.s1264.p1", "text": "Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.", "text_with_entity_marker": "Both [E1]GRB2[/E1] and sem-5 have been implicated in a highly conserved mechanism that regulates [E2]p21ras[/E2] signalling by receptor tyrosine kinases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[5, 9]], "entity_1_idx_in_text_with_entity_marker": [9, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[88, 94]], "entity_2_idx_in_text_with_entity_marker": [101, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1264_AIMed.d149.s1264.p2", "text": "Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.", "text_with_entity_marker": "Both GRB2 and [E1]sem-5[/E1] have been implicated in a highly conserved mechanism that regulates [E2]p21ras[/E2] signalling by receptor tyrosine kinases.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sem-5", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p21ras", "entity_2_idx": [[88, 94]], "entity_2_idx_in_text_with_entity_marker": [101, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1265_AIMed.d149.s1265.p0", "text": "In this report we show that in response to insulin, GRB2 forms a stable complex with two tyrosine-phosphorylated proteins.", "text_with_entity_marker": "In this report we show that in response to [E1]insulin[/E1], [E2]GRB2[/E2] forms a stable complex with two tyrosine-phosphorylated proteins.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[43, 50]], "entity_1_idx_in_text_with_entity_marker": [47, 54], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1266_AIMed.d149.s1266.p0", "text": "One protein is the major insulin receptor substrate IRS-1 and the second is the SH2 domain-containing oncogenic protein, Shc.", "text_with_entity_marker": "One protein is the major insulin receptor substrate [E1]IRS-1[/E1] and the second is the SH2 domain-containing oncogenic protein, [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p0", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between [E1]GRB2[/E1] and these two proteins require ligand activation of the [E2]insulin receptor[/E2] and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin receptor", "entity_2_idx": [[86, 102]], "entity_2_idx_in_text_with_entity_marker": [99, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p1", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between [E1]GRB2[/E1] and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of [E2]GRB2[/E2] to phosphotyrosines on both IRS-1 and Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[156, 160]], "entity_2_idx_in_text_with_entity_marker": [169, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p2", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between [E1]GRB2[/E1] and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both [E2]IRS-1[/E2] and Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p3", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between [E1]GRB2[/E1] and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[25, 29]], "entity_1_idx_in_text_with_entity_marker": [29, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[199, 202]], "entity_2_idx_in_text_with_entity_marker": [212, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p4", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between GRB2 and these two proteins require ligand activation of the [E1]insulin receptor[/E1] and are mediated by the binding of the SH2 domain of [E2]GRB2[/E2] to phosphotyrosines on both IRS-1 and Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[86, 102]], "entity_1_idx_in_text_with_entity_marker": [90, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[156, 160]], "entity_2_idx_in_text_with_entity_marker": [169, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p5", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between GRB2 and these two proteins require ligand activation of the [E1]insulin receptor[/E1] and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both [E2]IRS-1[/E2] and Shc.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[86, 102]], "entity_1_idx_in_text_with_entity_marker": [90, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p6", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between GRB2 and these two proteins require ligand activation of the [E1]insulin receptor[/E1] and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin receptor", "entity_1_idx": [[86, 102]], "entity_1_idx_in_text_with_entity_marker": [90, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[199, 202]], "entity_2_idx_in_text_with_entity_marker": [212, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p7", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of [E1]GRB2[/E1] to phosphotyrosines on both [E2]IRS-1[/E2] and Shc.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[156, 160]], "entity_1_idx_in_text_with_entity_marker": [160, 164], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p8", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of [E1]GRB2[/E1] to phosphotyrosines on both IRS-1 and [E2]Shc[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[156, 160]], "entity_1_idx_in_text_with_entity_marker": [160, 164], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[199, 202]], "entity_2_idx_in_text_with_entity_marker": [212, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1267_AIMed.d149.s1267.p9", "text": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.", "text_with_entity_marker": "The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both [E1]IRS-1[/E1] and [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[189, 194]], "entity_1_idx_in_text_with_entity_marker": [193, 198], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[199, 202]], "entity_2_idx_in_text_with_entity_marker": [212, 215], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p0", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although [E1]GRB2[/E1] associates with [E2]IRS-1[/E2] and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p1", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although [E1]GRB2[/E1] associates with IRS-1 and [E2]Shc[/E2], it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p2", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although [E1]GRB2[/E1] associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after [E2]insulin[/E2] stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[85, 92]], "entity_2_idx_in_text_with_entity_marker": [98, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p3", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although [E1]GRB2[/E1] associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that [E2]GRB2[/E2] is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p4", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although GRB2 associates with [E1]IRS-1[/E1] and [E2]Shc[/E2], it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p5", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although GRB2 associates with [E1]IRS-1[/E1] and Shc, it is not tyrosine-phosphorylated after [E2]insulin[/E2] stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[85, 92]], "entity_2_idx_in_text_with_entity_marker": [98, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p6", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although GRB2 associates with [E1]IRS-1[/E1] and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that [E2]GRB2[/E2] is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p7", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although GRB2 associates with IRS-1 and [E1]Shc[/E1], it is not tyrosine-phosphorylated after [E2]insulin[/E2] stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Shc", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[85, 92]], "entity_2_idx_in_text_with_entity_marker": [98, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p8", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although GRB2 associates with IRS-1 and [E1]Shc[/E1], it is not tyrosine-phosphorylated after insulin stimulation, implying that [E2]GRB2[/E2] is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Shc", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1268_AIMed.d149.s1268.p9", "text": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.", "text_with_entity_marker": "Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after [E1]insulin[/E1] stimulation, implying that [E2]GRB2[/E2] is not a substrate for the insulin receptor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[85, 92]], "entity_1_idx_in_text_with_entity_marker": [89, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[120, 124]], "entity_2_idx_in_text_with_entity_marker": [133, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1269_AIMed.d149.s1269.p0", "text": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.", "text_with_entity_marker": "Furthermore, we have identified a short sequence motif (YV/IN) present in [E1]IRS-1[/E1], [E2]EGFR[/E2] and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "EGFR", "entity_2_idx": [[81, 85]], "entity_2_idx_in_text_with_entity_marker": [94, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1269_AIMed.d149.s1269.p1", "text": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.", "text_with_entity_marker": "Furthermore, we have identified a short sequence motif (YV/IN) present in [E1]IRS-1[/E1], EGFR and [E2]Shc[/E2], which specifically binds the SH2 domain of GRB2 with high affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1269_AIMed.d149.s1269.p2", "text": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.", "text_with_entity_marker": "Furthermore, we have identified a short sequence motif (YV/IN) present in [E1]IRS-1[/E1], EGFR and Shc, which specifically binds the SH2 domain of [E2]GRB2[/E2] with high affinity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IRS-1", "entity_1_idx": [[74, 79]], "entity_1_idx_in_text_with_entity_marker": [78, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1269_AIMed.d149.s1269.p3", "text": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.", "text_with_entity_marker": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, [E1]EGFR[/E1] and [E2]Shc[/E2], which specifically binds the SH2 domain of GRB2 with high affinity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "EGFR", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1269_AIMed.d149.s1269.p4", "text": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.", "text_with_entity_marker": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, [E1]EGFR[/E1] and Shc, which specifically binds the SH2 domain of [E2]GRB2[/E2] with high affinity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "EGFR", "entity_1_idx": [[81, 85]], "entity_1_idx_in_text_with_entity_marker": [85, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1269_AIMed.d149.s1269.p5", "text": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.", "text_with_entity_marker": "Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and [E1]Shc[/E1], which specifically binds the SH2 domain of [E2]GRB2[/E2] with high affinity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Shc", "entity_1_idx": [[90, 93]], "entity_1_idx_in_text_with_entity_marker": [94, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GRB2", "entity_2_idx": [[138, 142]], "entity_2_idx_in_text_with_entity_marker": [151, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1270_AIMed.d149.s1270.p0", "text": "Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "text_with_entity_marker": "Interestingly, both [E1]GRB2[/E1] and [E2]phosphatidylinositol-3 (PI-3) kinase[/E2] can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "phosphatidylinositol-3 (PI-3) kinase", "entity_2_idx": [[29, 65]], "entity_2_idx_in_text_with_entity_marker": [42, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1270_AIMed.d149.s1270.p1", "text": "Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "text_with_entity_marker": "Interestingly, both [E1]GRB2[/E1] and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same [E2]IRS-1[/E2] molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[143, 148]], "entity_2_idx_in_text_with_entity_marker": [156, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1270_AIMed.d149.s1270.p2", "text": "Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "text_with_entity_marker": "Interestingly, both [E1]GRB2[/E1] and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby [E2]IRS-1[/E2] could provide the core for a large signalling complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GRB2", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1270_AIMed.d149.s1270.p3", "text": "Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "text_with_entity_marker": "Interestingly, both GRB2 and [E1]phosphatidylinositol-3 (PI-3) kinase[/E1] can simultaneously bind distinct tyrosine phosphorylated regions on the same [E2]IRS-1[/E2] molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "phosphatidylinositol-3 (PI-3) kinase", "entity_1_idx": [[29, 65]], "entity_1_idx_in_text_with_entity_marker": [33, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[143, 148]], "entity_2_idx_in_text_with_entity_marker": [156, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1270_AIMed.d149.s1270.p4", "text": "Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "text_with_entity_marker": "Interestingly, both GRB2 and [E1]phosphatidylinositol-3 (PI-3) kinase[/E1] can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby [E2]IRS-1[/E2] could provide the core for a large signalling complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "phosphatidylinositol-3 (PI-3) kinase", "entity_1_idx": [[29, 65]], "entity_1_idx_in_text_with_entity_marker": [33, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1270_AIMed.d149.s1270.p5", "text": "Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.", "text_with_entity_marker": "Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same [E1]IRS-1[/E1] molecule, suggesting a mechanism whereby [E2]IRS-1[/E2] could provide the core for a large signalling complex.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[143, 148]], "entity_1_idx_in_text_with_entity_marker": [147, 152], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[190, 195]], "entity_2_idx_in_text_with_entity_marker": [203, 208], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1271_AIMed.d149.s1271.p0", "text": "We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.", "text_with_entity_marker": "We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between [E1]GRB2[/E1] and the two targets [E2]IRS-1[/E2] and Shc.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IRS-1", "entity_2_idx": [[141, 146]], "entity_2_idx_in_text_with_entity_marker": [154, 159], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1271_AIMed.d149.s1271.p1", "text": "We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.", "text_with_entity_marker": "We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between [E1]GRB2[/E1] and the two targets IRS-1 and [E2]Shc[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GRB2", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[151, 154]], "entity_2_idx_in_text_with_entity_marker": [164, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d149.s1271_AIMed.d149.s1271.p2", "text": "We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.", "text_with_entity_marker": "We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets [E1]IRS-1[/E1] and [E2]Shc[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IRS-1", "entity_1_idx": [[141, 146]], "entity_1_idx_in_text_with_entity_marker": [145, 150], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Shc", "entity_2_idx": [[151, 154]], "entity_2_idx_in_text_with_entity_marker": [164, 167], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s977_AIMed.d116.s977.p0", "text": "Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product.", "text_with_entity_marker": "Activity of RNA polymerase I transcription factor [E1]UBF[/E1] blocked by [E2]Rb[/E2] gene product.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "UBF", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[65, 67]], "entity_2_idx_in_text_with_entity_marker": [78, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s978_AIMed.d116.s978.p0", "text": "The protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a tumour suppressor and negative growth regulator.", "text_with_entity_marker": "The protein encoded by the [E1]retinoblastoma susceptibility gene[/E1] ([E2]Rb[/E2]) functions as a tumour suppressor and negative growth regulator.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma susceptibility gene", "entity_1_idx": [[27, 61]], "entity_1_idx_in_text_with_entity_marker": [31, 65], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[63, 65]], "entity_2_idx_in_text_with_entity_marker": [76, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p0", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of [E1]Rb[/E1] protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of [E2]Rb[/E2] to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[52, 54]], "entity_1_idx_in_text_with_entity_marker": [56, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[180, 182]], "entity_2_idx_in_text_with_entity_marker": [193, 195], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p1", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of [E1]Rb[/E1] protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional [E2]Rb[/E2] pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[52, 54]], "entity_1_idx_in_text_with_entity_marker": [56, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[305, 307]], "entity_2_idx_in_text_with_entity_marker": [318, 320], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p2", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of [E1]Rb[/E1] protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) [E2]Rb[/E2] specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[52, 54]], "entity_1_idx_in_text_with_entity_marker": [56, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[324, 326]], "entity_2_idx_in_text_with_entity_marker": [337, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p3", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of [E1]Rb[/E1] protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor [E2]UBF[/E2] (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[52, 54]], "entity_1_idx_in_text_with_entity_marker": [56, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBF", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p4", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of [E1]Rb[/E1] protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ([E2]upstream binding factor[/E2]) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[52, 54]], "entity_1_idx_in_text_with_entity_marker": [56, 58], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "upstream binding factor", "entity_2_idx": [[412, 435]], "entity_2_idx_in_text_with_entity_marker": [425, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p5", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of [E1]Rb[/E1] to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional [E2]Rb[/E2] pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[180, 182]], "entity_1_idx_in_text_with_entity_marker": [184, 186], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[305, 307]], "entity_2_idx_in_text_with_entity_marker": [318, 320], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p6", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of [E1]Rb[/E1] to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) [E2]Rb[/E2] specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[180, 182]], "entity_1_idx_in_text_with_entity_marker": [184, 186], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[324, 326]], "entity_2_idx_in_text_with_entity_marker": [337, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p7", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of [E1]Rb[/E1] to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor [E2]UBF[/E2] (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[180, 182]], "entity_1_idx_in_text_with_entity_marker": [184, 186], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBF", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p8", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of [E1]Rb[/E1] to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ([E2]upstream binding factor[/E2]) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[180, 182]], "entity_1_idx_in_text_with_entity_marker": [184, 186], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "upstream binding factor", "entity_2_idx": [[412, 435]], "entity_2_idx_in_text_with_entity_marker": [425, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p9", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional [E1]Rb[/E1] pocket; and (4) [E2]Rb[/E2] specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[305, 307]], "entity_1_idx_in_text_with_entity_marker": [309, 311], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[324, 326]], "entity_2_idx_in_text_with_entity_marker": [337, 339], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p10", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional [E1]Rb[/E1] pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor [E2]UBF[/E2] (upstream binding factor) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[305, 307]], "entity_1_idx_in_text_with_entity_marker": [309, 311], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBF", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p11", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional [E1]Rb[/E1] pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ([E2]upstream binding factor[/E2]) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[305, 307]], "entity_1_idx_in_text_with_entity_marker": [309, 311], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "upstream binding factor", "entity_2_idx": [[412, 435]], "entity_2_idx_in_text_with_entity_marker": [425, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p12", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) [E1]Rb[/E1] specifically inhibits the activity of the RNA polymerase I transcription factor [E2]UBF[/E2] (upstream binding factor) in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Rb", "entity_1_idx": [[324, 326]], "entity_1_idx_in_text_with_entity_marker": [328, 330], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBF", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p13", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) [E1]Rb[/E1] specifically inhibits the activity of the RNA polymerase I transcription factor UBF ([E2]upstream binding factor[/E2]) in vitro.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Rb", "entity_1_idx": [[324, 326]], "entity_1_idx_in_text_with_entity_marker": [328, 330], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "upstream binding factor", "entity_2_idx": [[412, 435]], "entity_2_idx_in_text_with_entity_marker": [425, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s980_AIMed.d116.s980.p14", "text": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.", "text_with_entity_marker": "Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor [E1]UBF[/E1] ([E2]upstream binding factor[/E2]) in vitro.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "UBF", "entity_1_idx": [[407, 410]], "entity_1_idx_in_text_with_entity_marker": [411, 414], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "upstream binding factor", "entity_2_idx": [[412, 435]], "entity_2_idx_in_text_with_entity_marker": [425, 448], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s981_AIMed.d116.s981.p0", "text": "This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between Rb and UBF.", "text_with_entity_marker": "This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between [E1]Rb[/E1] and [E2]UBF[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Rb", "entity_1_idx": [[130, 132]], "entity_1_idx_in_text_with_entity_marker": [134, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "UBF", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d116.s982_AIMed.d116.s982.p0", "text": "These results indicate that there is an additional mechanism by which Rb suppresses cell growth, namely that Rb directly represses transcription of the rRNA genes.", "text_with_entity_marker": "These results indicate that there is an additional mechanism by which [E1]Rb[/E1] suppresses cell growth, namely that [E2]Rb[/E2] directly represses transcription of the rRNA genes.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[70, 72]], "entity_1_idx_in_text_with_entity_marker": [74, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[109, 111]], "entity_2_idx_in_text_with_entity_marker": [122, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s469_AIMed.d53.s469.p0", "text": "Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 (IL-6) that activates human gp130.", "text_with_entity_marker": "Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human [E1]interleukin-6[/E1] ([E2]IL-6[/E2]) that activates human gp130.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "interleukin-6", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s469_AIMed.d53.s469.p1", "text": "Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 (IL-6) that activates human gp130.", "text_with_entity_marker": "Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human [E1]interleukin-6[/E1] (IL-6) that activates human [E2]gp130[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "interleukin-6", "entity_1_idx": [[78, 91]], "entity_1_idx_in_text_with_entity_marker": [82, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s469_AIMed.d53.s469.p2", "text": "Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 (IL-6) that activates human gp130.", "text_with_entity_marker": "Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 ([E1]IL-6[/E1]) that activates human [E2]gp130[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s470_AIMed.d53.s470.p0", "text": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.", "text_with_entity_marker": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral [E1]IL-6[/E1] and human [E2]gp130[/E2], two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[92, 96]], "entity_1_idx_in_text_with_entity_marker": [96, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s470_AIMed.d53.s470.p1", "text": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.", "text_with_entity_marker": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral [E1]IL-6[/E1] and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of [E2]gp130[/E2] and site III of viral IL-6, which is necessary for receptor activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[92, 96]], "entity_1_idx_in_text_with_entity_marker": [96, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[226, 231]], "entity_2_idx_in_text_with_entity_marker": [239, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s470_AIMed.d53.s470.p2", "text": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.", "text_with_entity_marker": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral [E1]IL-6[/E1] and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral [E2]IL-6[/E2], which is necessary for receptor activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[92, 96]], "entity_1_idx_in_text_with_entity_marker": [96, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[254, 258]], "entity_2_idx_in_text_with_entity_marker": [267, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s470_AIMed.d53.s470.p3", "text": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.", "text_with_entity_marker": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human [E1]gp130[/E1], two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of [E2]gp130[/E2] and site III of viral IL-6, which is necessary for receptor activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[107, 112]], "entity_1_idx_in_text_with_entity_marker": [111, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[226, 231]], "entity_2_idx_in_text_with_entity_marker": [239, 244], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s470_AIMed.d53.s470.p4", "text": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.", "text_with_entity_marker": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human [E1]gp130[/E1], two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral [E2]IL-6[/E2], which is necessary for receptor activation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[107, 112]], "entity_1_idx_in_text_with_entity_marker": [111, 116], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[254, 258]], "entity_2_idx_in_text_with_entity_marker": [267, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s470_AIMed.d53.s470.p5", "text": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation.", "text_with_entity_marker": "In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of [E1]gp130[/E1] and site III of viral [E2]IL-6[/E2], which is necessary for receptor activation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "gp130", "entity_1_idx": [[226, 231]], "entity_1_idx_in_text_with_entity_marker": [230, 235], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[254, 258]], "entity_2_idx_in_text_with_entity_marker": [267, 271], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s471_AIMed.d53.s471.p0", "text": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.", "text_with_entity_marker": "Unlike human [E1]IL-6[/E1] (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact [E2]gp130[/E2], which enhances the complementarity of the viral IL-6-gp130 binding interfaces.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[125, 130]], "entity_2_idx_in_text_with_entity_marker": [138, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s471_AIMed.d53.s471.p1", "text": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.", "text_with_entity_marker": "Unlike human [E1]IL-6[/E1] (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral [E2]IL-6[/E2]-gp130 binding interfaces.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s471_AIMed.d53.s471.p2", "text": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.", "text_with_entity_marker": "Unlike human [E1]IL-6[/E1] (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-[E2]gp130[/E2] binding interfaces.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IL-6", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[185, 190]], "entity_2_idx_in_text_with_entity_marker": [198, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s471_AIMed.d53.s471.p3", "text": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.", "text_with_entity_marker": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact [E1]gp130[/E1], which enhances the complementarity of the viral [E2]IL-6[/E2]-gp130 binding interfaces.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[125, 130]], "entity_1_idx_in_text_with_entity_marker": [129, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6", "entity_2_idx": [[180, 184]], "entity_2_idx_in_text_with_entity_marker": [193, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s471_AIMed.d53.s471.p4", "text": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.", "text_with_entity_marker": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact [E1]gp130[/E1], which enhances the complementarity of the viral IL-6-[E2]gp130[/E2] binding interfaces.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[125, 130]], "entity_1_idx_in_text_with_entity_marker": [129, 134], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[185, 190]], "entity_2_idx_in_text_with_entity_marker": [198, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s471_AIMed.d53.s471.p5", "text": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces.", "text_with_entity_marker": "Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral [E1]IL-6[/E1]-[E2]gp130[/E2] binding interfaces.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[180, 184]], "entity_1_idx_in_text_with_entity_marker": [184, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[185, 190]], "entity_2_idx_in_text_with_entity_marker": [198, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d53.s472_AIMed.d53.s472.p0", "text": "The cross-reactivity of gp130 is apparently due to a chemical plasticity evident in the amphipathic gp130 cytokine-binding sites.", "text_with_entity_marker": "The cross-reactivity of [E1]gp130[/E1] is apparently due to a chemical plasticity evident in the amphipathic [E2]gp130[/E2] cytokine-binding sites.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "gp130", "entity_1_idx": [[24, 29]], "entity_1_idx_in_text_with_entity_marker": [28, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "gp130", "entity_2_idx": [[100, 105]], "entity_2_idx_in_text_with_entity_marker": [113, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s609_AIMed.d72.s609.p0", "text": "A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product.", "text_with_entity_marker": "A cellular protein that competes with [E1]SV40 T antigen[/E1] for binding to the [E2]retinoblastoma[/E2] gene product.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SV40 T antigen", "entity_1_idx": [[38, 52]], "entity_1_idx_in_text_with_entity_marker": [42, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "retinoblastoma", "entity_2_idx": [[72, 86]], "entity_2_idx_in_text_with_entity_marker": [85, 99], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s610_AIMed.d72.s610.p0", "text": "Tumour-suppressor genes, such as the human retinoblastoma susceptibility gene (Rb), are widely recognized as being vital in the control of cell growth and tumour formation.", "text_with_entity_marker": "Tumour-suppressor genes, such as the human [E1]retinoblastoma susceptibility gene[/E1] ([E2]Rb[/E2]), are widely recognized as being vital in the control of cell growth and tumour formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "retinoblastoma susceptibility gene", "entity_1_idx": [[43, 77]], "entity_1_idx_in_text_with_entity_marker": [47, 81], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[79, 81]], "entity_2_idx_in_text_with_entity_marker": [92, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s612_AIMed.d72.s612.p0", "text": "How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.", "text_with_entity_marker": "How [E1]Rb[/E1] acts to bring about this suppression is not clear but one clue is that the [E2]Rb[/E2] protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[4, 6]], "entity_1_idx_in_text_with_entity_marker": [8, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[82, 84]], "entity_2_idx_in_text_with_entity_marker": [95, 97], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s612_AIMed.d72.s612.p1", "text": "How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.", "text_with_entity_marker": "How [E1]Rb[/E1] acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of [E2]Rb[/E2] essential for such binding frequently contain mutations in tumour cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[4, 6]], "entity_1_idx_in_text_with_entity_marker": [8, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[199, 201]], "entity_2_idx_in_text_with_entity_marker": [212, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s612_AIMed.d72.s612.p2", "text": "How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.", "text_with_entity_marker": "How Rb acts to bring about this suppression is not clear but one clue is that the [E1]Rb[/E1] protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of [E2]Rb[/E2] essential for such binding frequently contain mutations in tumour cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[82, 84]], "entity_1_idx_in_text_with_entity_marker": [86, 88], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[199, 201]], "entity_2_idx_in_text_with_entity_marker": [212, 214], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s614_AIMed.d72.s614.p0", "text": "We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).", "text_with_entity_marker": "We report here the identification of one such human cellular [E1-E2]Rb[/E1]-associated protein[/E2] of relative molecular mass 46,000 (46K) (RbAP46).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[61, 63]], "entity_1_idx_in_text_with_entity_marker": [68, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb[/E1]-associated protein", "entity_2_idx": [[61, 82]], "entity_2_idx_in_text_with_entity_marker": [68, 94], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s614_AIMed.d72.s614.p1", "text": "We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).", "text_with_entity_marker": "We report here the identification of one such human cellular [E1]Rb[/E1]-associated protein of relative molecular mass 46,000 (46K) ([E2]RbAP46[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[61, 63]], "entity_1_idx_in_text_with_entity_marker": [65, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[124, 130]], "entity_2_idx_in_text_with_entity_marker": [137, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s614_AIMed.d72.s614.p2", "text": "We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).", "text_with_entity_marker": "We report here the identification of one such human cellular [E1]Rb-associated protein[/E1] of relative molecular mass 46,000 (46K) ([E2]RbAP46[/E2]).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb-associated protein", "entity_1_idx": [[61, 82]], "entity_1_idx_in_text_with_entity_marker": [65, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[124, 130]], "entity_2_idx_in_text_with_entity_marker": [137, 143], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p0", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that [E1]RbAP46[/E1] and [E2]simian virus 40 T antigen[/E2] have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[46, 52]], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "simian virus 40 T antigen", "entity_2_idx": [[57, 82]], "entity_2_idx_in_text_with_entity_marker": [70, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p1", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that [E1]RbAP46[/E1] and simian virus 40 T antigen have homologous [E2]Rb[/E2]-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RbAP46", "entity_1_idx": [[46, 52]], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[99, 101]], "entity_2_idx_in_text_with_entity_marker": [112, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p2", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that [E1]RbAP46[/E1] and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated [E2]Rb[/E2] proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[46, 52]], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[145, 147]], "entity_2_idx_in_text_with_entity_marker": [158, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p3", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that [E1]RbAP46[/E1] and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with [E2]RbAP46[/E2]; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[46, 52]], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[210, 216]], "entity_2_idx_in_text_with_entity_marker": [223, 229], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p4", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that [E1]RbAP46[/E1] and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with [E2]RbAP46[/E2] for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[46, 52]], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[307, 313]], "entity_2_idx_in_text_with_entity_marker": [320, 326], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p5", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that [E1]RbAP46[/E1] and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to [E2]Rb[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[46, 52]], "entity_1_idx_in_text_with_entity_marker": [50, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[329, 331]], "entity_2_idx_in_text_with_entity_marker": [342, 344], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p6", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and [E1]simian virus 40 T antigen[/E1] have homologous [E2]Rb[/E2]-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "simian virus 40 T antigen", "entity_1_idx": [[57, 82]], "entity_1_idx_in_text_with_entity_marker": [61, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[99, 101]], "entity_2_idx_in_text_with_entity_marker": [112, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p7", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and [E1]simian virus 40 T antigen[/E1] have homologous Rb-binding properties: first, several mutated [E2]Rb[/E2] proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "simian virus 40 T antigen", "entity_1_idx": [[57, 82]], "entity_1_idx_in_text_with_entity_marker": [61, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[145, 147]], "entity_2_idx_in_text_with_entity_marker": [158, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p8", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and [E1]simian virus 40 T antigen[/E1] have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with [E2]RbAP46[/E2]; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "simian virus 40 T antigen", "entity_1_idx": [[57, 82]], "entity_1_idx_in_text_with_entity_marker": [61, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[210, 216]], "entity_2_idx_in_text_with_entity_marker": [223, 229], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p9", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and [E1]simian virus 40 T antigen[/E1] have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with [E2]RbAP46[/E2] for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "simian virus 40 T antigen", "entity_1_idx": [[57, 82]], "entity_1_idx_in_text_with_entity_marker": [61, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[307, 313]], "entity_2_idx_in_text_with_entity_marker": [320, 326], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p10", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and [E1]simian virus 40 T antigen[/E1] have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to [E2]Rb[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "simian virus 40 T antigen", "entity_1_idx": [[57, 82]], "entity_1_idx_in_text_with_entity_marker": [61, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[329, 331]], "entity_2_idx_in_text_with_entity_marker": [342, 344], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p11", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous [E1]Rb[/E1]-binding properties: first, several mutated [E2]Rb[/E2] proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[99, 101]], "entity_1_idx_in_text_with_entity_marker": [103, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[145, 147]], "entity_2_idx_in_text_with_entity_marker": [158, 160], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p12", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous [E1]Rb[/E1]-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with [E2]RbAP46[/E2]; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[99, 101]], "entity_1_idx_in_text_with_entity_marker": [103, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[210, 216]], "entity_2_idx_in_text_with_entity_marker": [223, 229], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p13", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous [E1]Rb[/E1]-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with [E2]RbAP46[/E2] for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[99, 101]], "entity_1_idx_in_text_with_entity_marker": [103, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[307, 313]], "entity_2_idx_in_text_with_entity_marker": [320, 326], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p14", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous [E1]Rb[/E1]-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to [E2]Rb[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[99, 101]], "entity_1_idx_in_text_with_entity_marker": [103, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[329, 331]], "entity_2_idx_in_text_with_entity_marker": [342, 344], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p15", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated [E1]Rb[/E1] proteins that failed to bind to T also did not associate with [E2]RbAP46[/E2]; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[145, 147]], "entity_1_idx_in_text_with_entity_marker": [149, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[210, 216]], "entity_2_idx_in_text_with_entity_marker": [223, 229], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p16", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated [E1]Rb[/E1] proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with [E2]RbAP46[/E2] for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[145, 147]], "entity_1_idx_in_text_with_entity_marker": [149, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[307, 313]], "entity_2_idx_in_text_with_entity_marker": [320, 326], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p17", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated [E1]Rb[/E1] proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to [E2]Rb[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rb", "entity_1_idx": [[145, 147]], "entity_1_idx_in_text_with_entity_marker": [149, 151], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[329, 331]], "entity_2_idx_in_text_with_entity_marker": [342, 344], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p18", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with [E1]RbAP46[/E1]; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with [E2]RbAP46[/E2] for binding to Rb.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[210, 216]], "entity_1_idx_in_text_with_entity_marker": [214, 220], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RbAP46", "entity_2_idx": [[307, 313]], "entity_2_idx_in_text_with_entity_marker": [320, 326], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p19", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with [E1]RbAP46[/E1]; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to [E2]Rb[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[210, 216]], "entity_1_idx_in_text_with_entity_marker": [214, 220], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[329, 331]], "entity_2_idx_in_text_with_entity_marker": [342, 344], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s615_AIMed.d72.s615.p20", "text": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.", "text_with_entity_marker": "Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with [E1]RbAP46[/E1] for binding to [E2]Rb[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RbAP46", "entity_1_idx": [[307, 313]], "entity_1_idx_in_text_with_entity_marker": [311, 317], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[329, 331]], "entity_2_idx_in_text_with_entity_marker": [342, 344], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d72.s616_AIMed.d72.s616.p0", "text": "The apparent targeting of the RbAP46-Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.", "text_with_entity_marker": "The apparent targeting of the [E1]RbAP46[/E1]-[E2]Rb[/E2] interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RbAP46", "entity_1_idx": [[30, 36]], "entity_1_idx_in_text_with_entity_marker": [34, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Rb", "entity_2_idx": [[37, 39]], "entity_2_idx_in_text_with_entity_marker": [50, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s37_AIMed.d4.s37.p0", "text": "Positive inotropic responses mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae.", "text_with_entity_marker": "Positive inotropic responses mediated by endothelin [E1]ET(A)[/E1] and [E2]ET(B)[/E2] receptors in human myocardial trabeculae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ET(A)", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET(B)", "entity_2_idx": [[62, 67]], "entity_2_idx_in_text_with_entity_marker": [75, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s38_AIMed.d4.s38.p0", "text": "The aim of the present study was to determine possible inotropic effects mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae from the right atrium and the left ventricle.", "text_with_entity_marker": "The aim of the present study was to determine possible inotropic effects mediated by endothelin [E1]ET(A)[/E1] and [E2]ET(B)[/E2] receptors in human myocardial trabeculae from the right atrium and the left ventricle.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ET(A)", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET(B)", "entity_2_idx": [[106, 111]], "entity_2_idx_in_text_with_entity_marker": [119, 124], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s40_AIMed.d4.s40.p0", "text": "Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.", "text_with_entity_marker": "[E1]Endothelin-1[/E1] ([E2]ET-1[/E2]) and ET-3 had a strong positive inotropic effect in all trabeculae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Endothelin-1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET-1", "entity_2_idx": [[14, 18]], "entity_2_idx_in_text_with_entity_marker": [27, 31], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s40_AIMed.d4.s40.p1", "text": "Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.", "text_with_entity_marker": "[E1]Endothelin-1[/E1] (ET-1) and [E2]ET-3[/E2] had a strong positive inotropic effect in all trabeculae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Endothelin-1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET-3", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s40_AIMed.d4.s40.p2", "text": "Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.", "text_with_entity_marker": "Endothelin-1 ([E1]ET-1[/E1]) and [E2]ET-3[/E2] had a strong positive inotropic effect in all trabeculae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ET-1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET-3", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s41_AIMed.d4.s41.p0", "text": "ET-1 was significantly more potent than ET-3 in both atrial (P < 0.001) and ventricular (P < 0.05) trabeculae.", "text_with_entity_marker": "[E1]ET-1[/E1] was significantly more potent than [E2]ET-3[/E2] in both atrial (P < 0.001) and ventricular (P < 0.05) trabeculae.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ET-1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET-3", "entity_2_idx": [[40, 44]], "entity_2_idx_in_text_with_entity_marker": [53, 57], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s42_AIMed.d4.s42.p0", "text": "Preincubation with the ET(A) receptor antagonist FR139317 (1 microM) decreased significantly (P < 0.005) the potency of ET- I in both atrial and ventricular trabeculae, without any significant changes in Emax (maximum effect obtained with an agonist).", "text_with_entity_marker": "Preincubation with the [E1]ET(A) receptor[/E1] antagonist FR139317 (1 microM) decreased significantly (P < 0.005) the potency of [E2]ET- I[/E2] in both atrial and ventricular trabeculae, without any significant changes in Emax (maximum effect obtained with an agonist).", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ET(A) receptor", "entity_1_idx": [[23, 37]], "entity_1_idx_in_text_with_entity_marker": [27, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET- I", "entity_2_idx": [[120, 125]], "entity_2_idx_in_text_with_entity_marker": [133, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s43_AIMed.d4.s43.p0", "text": "The ET(B) receptor agonist IRL 1620 had a positive inotropic effect only in some trabeculae, and the ET(B) receptor antagonist BQ 788 (1 microM) almost completely blocked this effect.", "text_with_entity_marker": "The [E1]ET(B) receptor[/E1] agonist IRL 1620 had a positive inotropic effect only in some trabeculae, and the [E2]ET(B) receptor[/E2] antagonist BQ 788 (1 microM) almost completely blocked this effect.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ET(B) receptor", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET(B) receptor", "entity_2_idx": [[101, 115]], "entity_2_idx_in_text_with_entity_marker": [114, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d4.s44_AIMed.d4.s44.p0", "text": "These results suggest that both ET(A) and ET(B) receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart.", "text_with_entity_marker": "These results suggest that both [E1]ET(A)[/E1] and [E2]ET(B)[/E2] receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "ET(A)", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ET(B)", "entity_2_idx": [[42, 47]], "entity_2_idx_in_text_with_entity_marker": [55, 60], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s970_AIMed.d115.s970.p0", "text": "Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor.", "text_with_entity_marker": "Interaction with [E1]RAP74[/E1] subunit of [E2]TFIIF[/E2] is required for transcriptional activation by serum response factor.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[17, 22]], "entity_1_idx_in_text_with_entity_marker": [21, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIF", "entity_2_idx": [[34, 39]], "entity_2_idx_in_text_with_entity_marker": [47, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s970_AIMed.d115.s970.p1", "text": "Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor.", "text_with_entity_marker": "Interaction with [E1]RAP74[/E1] subunit of TFIIF is required for transcriptional activation by [E2]serum response factor[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RAP74", "entity_1_idx": [[17, 22]], "entity_1_idx_in_text_with_entity_marker": [21, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "serum response factor", "entity_2_idx": [[86, 107]], "entity_2_idx_in_text_with_entity_marker": [99, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s970_AIMed.d115.s970.p2", "text": "Interaction with RAP74 subunit of TFIIF is required for transcriptional activation by serum response factor.", "text_with_entity_marker": "Interaction with RAP74 subunit of [E1]TFIIF[/E1] is required for transcriptional activation by [E2]serum response factor[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIF", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "serum response factor", "entity_2_idx": [[86, 107]], "entity_2_idx_in_text_with_entity_marker": [99, 120], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s971_AIMed.d115.s971.p0", "text": "A few general transcription factors, in particular TFIID and TFIIB, have been found to bind transcriptional activators.", "text_with_entity_marker": "A few general transcription factors, in particular [E1]TFIID[/E1] and [E2]TFIIB[/E2], have been found to bind transcriptional activators.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIID", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[61, 66]], "entity_2_idx_in_text_with_entity_marker": [74, 79], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s972_AIMed.d115.s972.p0", "text": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.", "text_with_entity_marker": "Here we show that the general transcription factor [E1]TFIIF[/E1] is also a target for a transcriptional activator, namely [E2]serum response factor[/E2] (SRF), which binds to the c-fos promoter.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIF", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "serum response factor", "entity_2_idx": [[114, 135]], "entity_2_idx_in_text_with_entity_marker": [127, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s972_AIMed.d115.s972.p1", "text": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.", "text_with_entity_marker": "Here we show that the general transcription factor [E1]TFIIF[/E1] is also a target for a transcriptional activator, namely serum response factor ([E2]SRF[/E2]), which binds to the c-fos promoter.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIF", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s972_AIMed.d115.s972.p2", "text": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.", "text_with_entity_marker": "Here we show that the general transcription factor [E1]TFIIF[/E1] is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the [E2]c-fos[/E2] promoter.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIF", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-fos", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s972_AIMed.d115.s972.p3", "text": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.", "text_with_entity_marker": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely [E1]serum response factor[/E1] ([E2]SRF[/E2]), which binds to the c-fos promoter.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serum response factor", "entity_1_idx": [[114, 135]], "entity_1_idx_in_text_with_entity_marker": [118, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s972_AIMed.d115.s972.p4", "text": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.", "text_with_entity_marker": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely [E1]serum response factor[/E1] (SRF), which binds to the [E2]c-fos[/E2] promoter.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "serum response factor", "entity_1_idx": [[114, 135]], "entity_1_idx_in_text_with_entity_marker": [118, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-fos", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s972_AIMed.d115.s972.p5", "text": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor (SRF), which binds to the c-fos promoter.", "text_with_entity_marker": "Here we show that the general transcription factor TFIIF is also a target for a transcriptional activator, namely serum response factor ([E1]SRF[/E1]), which binds to the [E2]c-fos[/E2] promoter.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRF", "entity_1_idx": [[137, 140]], "entity_1_idx_in_text_with_entity_marker": [141, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-fos", "entity_2_idx": [[162, 167]], "entity_2_idx_in_text_with_entity_marker": [175, 180], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s973_AIMed.d115.s973.p0", "text": "Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.", "text_with_entity_marker": "Using a yeast interaction assay, we find that [E1]SRF[/E1] binds the [E2]RAP74[/E2] subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SRF", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAP74", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s973_AIMed.d115.s973.p1", "text": "Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.", "text_with_entity_marker": "Using a yeast interaction assay, we find that [E1]SRF[/E1] binds the RAP74 subunit of [E2]TFIIF[/E2] and that SRF's transcriptional activation domain is the region involved in this binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRF", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIF", "entity_2_idx": [[77, 82]], "entity_2_idx_in_text_with_entity_marker": [90, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s973_AIMed.d115.s973.p2", "text": "Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.", "text_with_entity_marker": "Using a yeast interaction assay, we find that [E1]SRF[/E1] binds the RAP74 subunit of TFIIF and that [E2]SRF[/E2]'s transcriptional activation domain is the region involved in this binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRF", "entity_1_idx": [[46, 49]], "entity_1_idx_in_text_with_entity_marker": [50, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s973_AIMed.d115.s973.p3", "text": "Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.", "text_with_entity_marker": "Using a yeast interaction assay, we find that SRF binds the [E1]RAP74[/E1] subunit of [E2]TFIIF[/E2] and that SRF's transcriptional activation domain is the region involved in this binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIF", "entity_2_idx": [[77, 82]], "entity_2_idx_in_text_with_entity_marker": [90, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s973_AIMed.d115.s973.p4", "text": "Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.", "text_with_entity_marker": "Using a yeast interaction assay, we find that SRF binds the [E1]RAP74[/E1] subunit of TFIIF and that [E2]SRF[/E2]'s transcriptional activation domain is the region involved in this binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s973_AIMed.d115.s973.p5", "text": "Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of TFIIF and that SRF's transcriptional activation domain is the region involved in this binding.", "text_with_entity_marker": "Using a yeast interaction assay, we find that SRF binds the RAP74 subunit of [E1]TFIIF[/E1] and that [E2]SRF[/E2]'s transcriptional activation domain is the region involved in this binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIF", "entity_1_idx": [[77, 82]], "entity_1_idx_in_text_with_entity_marker": [81, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s974_AIMed.d115.s974.p0", "text": "Further, RAP74's central charged cluster domain is required for binding to SRF's activation domain.", "text_with_entity_marker": "Further, [E1]RAP74[/E1]'s central charged cluster domain is required for binding to [E2]SRF[/E2]'s activation domain.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[9, 14]], "entity_1_idx_in_text_with_entity_marker": [13, 18], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[75, 78]], "entity_2_idx_in_text_with_entity_marker": [88, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s975_AIMed.d115.s975.p0", "text": "Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription.", "text_with_entity_marker": "Deletion of this domain impairs [E1]RAP74[/E1]'s ability to support [E2]SRF[/E2]-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[59, 62]], "entity_2_idx_in_text_with_entity_marker": [72, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s975_AIMed.d115.s975.p1", "text": "Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription.", "text_with_entity_marker": "Deletion of this domain impairs [E1]RAP74[/E1]'s ability to support SRF-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support [E2]SP1[/E2]-activated transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SP1", "entity_2_idx": [[190, 193]], "entity_2_idx_in_text_with_entity_marker": [203, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s975_AIMed.d115.s975.p2", "text": "Deletion of this domain impairs RAP74's ability to support SRF-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support SP1-activated transcription.", "text_with_entity_marker": "Deletion of this domain impairs RAP74's ability to support [E1]SRF[/E1]-activated transcription in vitro but has little effect on the protein's basal transcription activity or its ability to support [E2]SP1[/E2]-activated transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRF", "entity_1_idx": [[59, 62]], "entity_1_idx_in_text_with_entity_marker": [63, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SP1", "entity_2_idx": [[190, 193]], "entity_2_idx_in_text_with_entity_marker": [203, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s976_AIMed.d115.s976.p0", "text": "The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.", "text_with_entity_marker": "The correlation of [E1]SRF[/E1]-[E2]RAP74[/E2] binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SRF", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAP74", "entity_2_idx": [[23, 28]], "entity_2_idx_in_text_with_entity_marker": [36, 41], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s976_AIMed.d115.s976.p1", "text": "The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.", "text_with_entity_marker": "The correlation of [E1]SRF[/E1]-RAP74 binding with transcriptional activation suggests that [E2]RAP74[/E2] is a critical target for SRF-activated transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRF", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAP74", "entity_2_idx": [[83, 88]], "entity_2_idx_in_text_with_entity_marker": [96, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s976_AIMed.d115.s976.p2", "text": "The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.", "text_with_entity_marker": "The correlation of [E1]SRF[/E1]-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for [E2]SRF[/E2]-activated transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRF", "entity_1_idx": [[19, 22]], "entity_1_idx_in_text_with_entity_marker": [23, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s976_AIMed.d115.s976.p3", "text": "The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.", "text_with_entity_marker": "The correlation of SRF-[E1]RAP74[/E1] binding with transcriptional activation suggests that [E2]RAP74[/E2] is a critical target for SRF-activated transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAP74", "entity_2_idx": [[83, 88]], "entity_2_idx_in_text_with_entity_marker": [96, 101], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s976_AIMed.d115.s976.p4", "text": "The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.", "text_with_entity_marker": "The correlation of SRF-[E1]RAP74[/E1] binding with transcriptional activation suggests that RAP74 is a critical target for [E2]SRF[/E2]-activated transcription.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "RAP74", "entity_1_idx": [[23, 28]], "entity_1_idx_in_text_with_entity_marker": [27, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d115.s976_AIMed.d115.s976.p5", "text": "The correlation of SRF-RAP74 binding with transcriptional activation suggests that RAP74 is a critical target for SRF-activated transcription.", "text_with_entity_marker": "The correlation of SRF-RAP74 binding with transcriptional activation suggests that [E1]RAP74[/E1] is a critical target for [E2]SRF[/E2]-activated transcription.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "RAP74", "entity_1_idx": [[83, 88]], "entity_1_idx_in_text_with_entity_marker": [87, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SRF", "entity_2_idx": [[114, 117]], "entity_2_idx_in_text_with_entity_marker": [127, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s784_AIMed.d92.s784.p0", "text": "A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation.", "text_with_entity_marker": "A potential interaction of [E1]p75[/E1] and [E2]trkA[/E2] NGF receptors revealed by affinity crosslinking and immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trkA", "entity_2_idx": [[35, 39]], "entity_2_idx_in_text_with_entity_marker": [48, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s784_AIMed.d92.s784.p1", "text": "A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation.", "text_with_entity_marker": "A potential interaction of [E1]p75[/E1] and trkA [E2]NGF[/E2] receptors revealed by affinity crosslinking and immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s784_AIMed.d92.s784.p2", "text": "A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation.", "text_with_entity_marker": "A potential interaction of p75 and [E1]trkA[/E1] [E2]NGF[/E2] receptors revealed by affinity crosslinking and immunoprecipitation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[35, 39]], "entity_1_idx_in_text_with_entity_marker": [39, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p0", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "[E1]Nerve growth factor[/E1] binds independently to two transmembrane receptors, the [E2]p75[/E2] neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Nerve growth factor", "entity_1_idx": [[0, 19]], "entity_1_idx_in_text_with_entity_marker": [4, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[76, 79]], "entity_2_idx_in_text_with_entity_marker": [89, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p1", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "[E1]Nerve growth factor[/E1] binds independently to two transmembrane receptors, the [E2]p75 neurotrophin receptor[/E2] and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Nerve growth factor", "entity_1_idx": [[0, 19]], "entity_1_idx_in_text_with_entity_marker": [4, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75 neurotrophin receptor", "entity_2_idx": [[76, 101]], "entity_2_idx_in_text_with_entity_marker": [89, 114], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p2", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "[E1]Nerve growth factor[/E1] binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the [E2]p140trk[/E2] (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Nerve growth factor", "entity_1_idx": [[0, 19]], "entity_1_idx_in_text_with_entity_marker": [4, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p140trk", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p3", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "[E1]Nerve growth factor[/E1] binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk ([E2]trkA[/E2]) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Nerve growth factor", "entity_1_idx": [[0, 19]], "entity_1_idx_in_text_with_entity_marker": [4, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trkA", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p4", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "[E1]Nerve growth factor[/E1] binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the [E2]p140trk (trkA) tyrosine kinase receptor[/E2], which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Nerve growth factor", "entity_1_idx": [[0, 19]], "entity_1_idx_in_text_with_entity_marker": [4, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p140trk (trkA) tyrosine kinase receptor", "entity_2_idx": [[110, 149]], "entity_2_idx_in_text_with_entity_marker": [123, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p5", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "[E1]Nerve growth factor[/E1] binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to [E2]NGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Nerve growth factor", "entity_1_idx": [[0, 19]], "entity_1_idx_in_text_with_entity_marker": [4, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[229, 232]], "entity_2_idx_in_text_with_entity_marker": [242, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p6", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1-E2]p75[/E1] neurotrophin receptor[/E2] and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[76, 79]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75[/E1] neurotrophin receptor", "entity_2_idx": [[76, 101]], "entity_2_idx_in_text_with_entity_marker": [83, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p7", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75[/E1] neurotrophin receptor and the [E2]p140trk[/E2] (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[76, 79]], "entity_1_idx_in_text_with_entity_marker": [80, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p140trk", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p8", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75[/E1] neurotrophin receptor and the p140trk ([E2]trkA[/E2]) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[76, 79]], "entity_1_idx_in_text_with_entity_marker": [80, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trkA", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p9", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75[/E1] neurotrophin receptor and the [E2]p140trk (trkA) tyrosine kinase receptor[/E2], which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[76, 79]], "entity_1_idx_in_text_with_entity_marker": [80, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p140trk (trkA) tyrosine kinase receptor", "entity_2_idx": [[110, 149]], "entity_2_idx_in_text_with_entity_marker": [123, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p10", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75[/E1] neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to [E2]NGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[76, 79]], "entity_1_idx_in_text_with_entity_marker": [80, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[229, 232]], "entity_2_idx_in_text_with_entity_marker": [242, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p11", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75 neurotrophin receptor[/E1] and the [E2]p140trk[/E2] (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75 neurotrophin receptor", "entity_1_idx": [[76, 101]], "entity_1_idx_in_text_with_entity_marker": [80, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p140trk", "entity_2_idx": [[110, 117]], "entity_2_idx_in_text_with_entity_marker": [123, 130], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p12", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75 neurotrophin receptor[/E1] and the p140trk ([E2]trkA[/E2]) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75 neurotrophin receptor", "entity_1_idx": [[76, 101]], "entity_1_idx_in_text_with_entity_marker": [80, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trkA", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p13", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75 neurotrophin receptor[/E1] and the [E2]p140trk (trkA) tyrosine kinase receptor[/E2], which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75 neurotrophin receptor", "entity_1_idx": [[76, 101]], "entity_1_idx_in_text_with_entity_marker": [80, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p140trk (trkA) tyrosine kinase receptor", "entity_2_idx": [[110, 149]], "entity_2_idx_in_text_with_entity_marker": [123, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p14", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the [E1]p75 neurotrophin receptor[/E1] and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to [E2]NGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75 neurotrophin receptor", "entity_1_idx": [[76, 101]], "entity_1_idx_in_text_with_entity_marker": [80, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[229, 232]], "entity_2_idx_in_text_with_entity_marker": [242, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p15", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the [E1]p140trk[/E1] ([E2]trkA[/E2]) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p140trk", "entity_1_idx": [[110, 117]], "entity_1_idx_in_text_with_entity_marker": [114, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trkA", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [132, 136], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p16", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the [E1-E2]p140trk[/E1] (trkA) tyrosine kinase receptor[/E2], which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p140trk", "entity_1_idx": [[110, 117]], "entity_1_idx_in_text_with_entity_marker": [117, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p140trk[/E1] (trkA) tyrosine kinase receptor", "entity_2_idx": [[110, 149]], "entity_2_idx_in_text_with_entity_marker": [117, 161], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p17", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the [E1]p140trk[/E1] (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to [E2]NGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p140trk", "entity_1_idx": [[110, 117]], "entity_1_idx_in_text_with_entity_marker": [114, 121], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[229, 232]], "entity_2_idx_in_text_with_entity_marker": [242, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p18", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the [E1]p140trk (trkA) tyrosine kinase receptor[/E1][E2]trkA[/E2]) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p140trk (trkA) tyrosine kinase receptor", "entity_1_idx": [[110, 149]], "entity_1_idx_in_text_with_entity_marker": [114, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trkA", "entity_2_idx": [[119, 123]], "entity_2_idx_in_text_with_entity_marker": [162, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p19", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk ([E1]trkA[/E1]) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to [E2]NGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[119, 123]], "entity_1_idx_in_text_with_entity_marker": [123, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[229, 232]], "entity_2_idx_in_text_with_entity_marker": [242, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s785_AIMed.d92.s785.p20", "text": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the p140trk (trkA) tyrosine kinase receptor, which are both co-expressed in the majority of neuronal cells that respond to NGF.", "text_with_entity_marker": "Nerve growth factor binds independently to two transmembrane receptors, the p75 neurotrophin receptor and the [E1]p140trk (trkA) tyrosine kinase receptor[/E1], which are both co-expressed in the majority of neuronal cells that respond to [E2]NGF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p140trk (trkA) tyrosine kinase receptor", "entity_1_idx": [[110, 149]], "entity_1_idx_in_text_with_entity_marker": [114, 153], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[229, 232]], "entity_2_idx_in_text_with_entity_marker": [242, 245], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s787_AIMed.d92.s787.p0", "text": "Here we have utilized affinity crosslinking agents with 125I-NGF to detect an association of trkA and p75 receptors in embryonic spinal cord and brain tissues enriched in the two receptors.", "text_with_entity_marker": "Here we have utilized affinity crosslinking agents with 125I-NGF to detect an association of [E1]trkA[/E1] and [E2]p75[/E2] receptors in embryonic spinal cord and brain tissues enriched in the two receptors.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[93, 97]], "entity_1_idx_in_text_with_entity_marker": [97, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p0", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and [E2]p75[/E2] were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[42, 45]], "entity_2_idx_in_text_with_entity_marker": [55, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p1", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF[/E2]-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p2", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF-receptor[/E2] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF-receptor", "entity_2_idx": [[126, 138]], "entity_2_idx_in_text_with_entity_marker": [139, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p3", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p4", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p5", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF[/E2]-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p6", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF-receptor[/E2] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF-receptor", "entity_2_idx": [[126, 138]], "entity_2_idx_in_text_with_entity_marker": [139, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p7", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p8", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p9", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1-E2]NGF[/E1]-receptor[/E2] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[126, 129]], "entity_1_idx_in_text_with_entity_marker": [133, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF[/E1]-receptor", "entity_2_idx": [[126, 138]], "entity_2_idx_in_text_with_entity_marker": [133, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p10", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF[/E1]-receptor complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[126, 129]], "entity_1_idx_in_text_with_entity_marker": [130, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p11", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF[/E1]-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF", "entity_1_idx": [[126, 129]], "entity_1_idx_in_text_with_entity_marker": [130, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p12", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF-receptor[/E1] complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF-receptor", "entity_1_idx": [[126, 138]], "entity_1_idx_in_text_with_entity_marker": [130, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p13", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF-receptor[/E1] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NGF-receptor", "entity_1_idx": [[126, 138]], "entity_1_idx_in_text_with_entity_marker": [130, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p14", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with [E1]trk[/E1]-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trk", "entity_1_idx": [[154, 157]], "entity_1_idx_in_text_with_entity_marker": [158, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s789_AIMed.d92.s789.p0", "text": "Our results indicate that the trkA and p75 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity NGF binding sites.", "text_with_entity_marker": "Our results indicate that the [E1]trkA[/E1] and [E2]p75[/E2] receptors can potentially interact, and that such an association may be responsible for the generation of high affinity NGF binding sites.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [34, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[39, 42]], "entity_2_idx_in_text_with_entity_marker": [52, 55], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s789_AIMed.d92.s789.p1", "text": "Our results indicate that the trkA and p75 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity NGF binding sites.", "text_with_entity_marker": "Our results indicate that the [E1]trkA[/E1] and p75 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity [E2]NGF[/E2] binding sites.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "trkA", "entity_1_idx": [[30, 34]], "entity_1_idx_in_text_with_entity_marker": [34, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s789_AIMed.d92.s789.p2", "text": "Our results indicate that the trkA and p75 receptors can potentially interact, and that such an association may be responsible for the generation of high affinity NGF binding sites.", "text_with_entity_marker": "Our results indicate that the trkA and [E1]p75[/E1] receptors can potentially interact, and that such an association may be responsible for the generation of high affinity [E2]NGF[/E2] binding sites.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p75", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[163, 166]], "entity_2_idx_in_text_with_entity_marker": [176, 179], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s820_AIMed.d97.s820.p0", "text": "Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to DAF-4, a BMP type II receptor from Caenorhabditis elegans.", "text_with_entity_marker": "Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ([E1]BMPR-II[/E1]), which is distantly related to [E2]DAF-4[/E2], a BMP type II receptor from Caenorhabditis elegans.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPR-II", "entity_1_idx": [[91, 98]], "entity_1_idx_in_text_with_entity_marker": [95, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "DAF-4", "entity_2_idx": [[131, 136]], "entity_2_idx_in_text_with_entity_marker": [144, 149], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s820_AIMed.d97.s820.p1", "text": "Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to DAF-4, a BMP type II receptor from Caenorhabditis elegans.", "text_with_entity_marker": "Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ([E1]BMPR-II[/E1]), which is distantly related to DAF-4, a [E2]BMP type II receptor[/E2] from Caenorhabditis elegans.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMPR-II", "entity_1_idx": [[91, 98]], "entity_1_idx_in_text_with_entity_marker": [95, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP type II receptor", "entity_2_idx": [[140, 160]], "entity_2_idx_in_text_with_entity_marker": [153, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s820_AIMed.d97.s820.p2", "text": "Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to DAF-4, a BMP type II receptor from Caenorhabditis elegans.", "text_with_entity_marker": "Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to [E1]DAF-4[/E1], a [E2]BMP type II receptor[/E2] from Caenorhabditis elegans.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "DAF-4", "entity_1_idx": [[131, 136]], "entity_1_idx_in_text_with_entity_marker": [135, 140], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP type II receptor", "entity_2_idx": [[140, 160]], "entity_2_idx_in_text_with_entity_marker": [153, 173], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s821_AIMed.d97.s821.p0", "text": "In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.", "text_with_entity_marker": "In transfected COS-1 cells, [E1]osteogenic protein (OP)-1[/E1]/[E2]BMP-7[/E2], and less efficiently BMP-4, bound to BMPR-II.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "osteogenic protein (OP)-1", "entity_1_idx": [[28, 53]], "entity_1_idx_in_text_with_entity_marker": [32, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-7", "entity_2_idx": [[54, 59]], "entity_2_idx_in_text_with_entity_marker": [67, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s821_AIMed.d97.s821.p1", "text": "In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.", "text_with_entity_marker": "In transfected COS-1 cells, [E1]osteogenic protein (OP)-1[/E1]/BMP-7, and less efficiently [E2]BMP-4[/E2], bound to BMPR-II.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "osteogenic protein (OP)-1", "entity_1_idx": [[28, 53]], "entity_1_idx_in_text_with_entity_marker": [32, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-4", "entity_2_idx": [[82, 87]], "entity_2_idx_in_text_with_entity_marker": [95, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s821_AIMed.d97.s821.p2", "text": "In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.", "text_with_entity_marker": "In transfected COS-1 cells, [E1]osteogenic protein (OP)-1[/E1]/BMP-7, and less efficiently BMP-4, bound to [E2]BMPR-II[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "osteogenic protein (OP)-1", "entity_1_idx": [[28, 53]], "entity_1_idx_in_text_with_entity_marker": [32, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[98, 105]], "entity_2_idx_in_text_with_entity_marker": [111, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s821_AIMed.d97.s821.p3", "text": "In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.", "text_with_entity_marker": "In transfected COS-1 cells, osteogenic protein (OP)-1/[E1]BMP-7[/E1], and less efficiently [E2]BMP-4[/E2], bound to BMPR-II.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "BMP-7", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-4", "entity_2_idx": [[82, 87]], "entity_2_idx_in_text_with_entity_marker": [95, 100], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s821_AIMed.d97.s821.p4", "text": "In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.", "text_with_entity_marker": "In transfected COS-1 cells, osteogenic protein (OP)-1/[E1]BMP-7[/E1], and less efficiently BMP-4, bound to [E2]BMPR-II[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-7", "entity_1_idx": [[54, 59]], "entity_1_idx_in_text_with_entity_marker": [58, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[98, 105]], "entity_2_idx_in_text_with_entity_marker": [111, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s821_AIMed.d97.s821.p5", "text": "In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently BMP-4, bound to BMPR-II.", "text_with_entity_marker": "In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently [E1]BMP-4[/E1], bound to [E2]BMPR-II[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-4", "entity_1_idx": [[82, 87]], "entity_1_idx_in_text_with_entity_marker": [86, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[98, 105]], "entity_2_idx_in_text_with_entity_marker": [111, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s823_AIMed.d97.s823.p0", "text": "Binding of OP-1/BMP-7 to BMPR-II was also observed in nontransfected cell lines.", "text_with_entity_marker": "Binding of [E1]OP-1[/E1]/[E2]BMP-7[/E2] to BMPR-II was also observed in nontransfected cell lines.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "OP-1", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-7", "entity_2_idx": [[16, 21]], "entity_2_idx_in_text_with_entity_marker": [29, 34], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s823_AIMed.d97.s823.p1", "text": "Binding of OP-1/BMP-7 to BMPR-II was also observed in nontransfected cell lines.", "text_with_entity_marker": "Binding of [E1]OP-1[/E1]/BMP-7 to [E2]BMPR-II[/E2] was also observed in nontransfected cell lines.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "OP-1", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[25, 32]], "entity_2_idx_in_text_with_entity_marker": [38, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s823_AIMed.d97.s823.p2", "text": "Binding of OP-1/BMP-7 to BMPR-II was also observed in nontransfected cell lines.", "text_with_entity_marker": "Binding of OP-1/[E1]BMP-7[/E1] to [E2]BMPR-II[/E2] was also observed in nontransfected cell lines.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMP-7", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMPR-II", "entity_2_idx": [[25, 32]], "entity_2_idx_in_text_with_entity_marker": [38, 45], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s824_AIMed.d97.s824.p0", "text": "Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by OP-1/BMP-7.", "text_with_entity_marker": "Moreover, a transcriptional activation signal was transduced by [E1]BMPR-II[/E1] in the presence of type I receptors after stimulation by [E2]OP-1[/E2]/BMP-7.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMPR-II", "entity_1_idx": [[64, 71]], "entity_1_idx_in_text_with_entity_marker": [68, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "OP-1", "entity_2_idx": [[129, 133]], "entity_2_idx_in_text_with_entity_marker": [142, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s824_AIMed.d97.s824.p1", "text": "Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by OP-1/BMP-7.", "text_with_entity_marker": "Moreover, a transcriptional activation signal was transduced by [E1]BMPR-II[/E1] in the presence of type I receptors after stimulation by OP-1/[E2]BMP-7[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "BMPR-II", "entity_1_idx": [[64, 71]], "entity_1_idx_in_text_with_entity_marker": [68, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-7", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d97.s824_AIMed.d97.s824.p2", "text": "Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by OP-1/BMP-7.", "text_with_entity_marker": "Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by [E1]OP-1[/E1]/[E2]BMP-7[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "OP-1", "entity_1_idx": [[129, 133]], "entity_1_idx_in_text_with_entity_marker": [133, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "BMP-7", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d17.s146_AIMed.d17.s146.p0", "text": "This overview summarizes the current knowledge on plasminogen activator inhibitor-1 (PAI-1) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation.", "text_with_entity_marker": "This overview summarizes the current knowledge on [E1]plasminogen activator inhibitor-1[/E1] ([E2]PAI-1[/E2]) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "plasminogen activator inhibitor-1", "entity_1_idx": [[50, 83]], "entity_1_idx_in_text_with_entity_marker": [54, 87], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PAI-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d17.s147_AIMed.d17.s147.p0", "text": "In addition, a possible role for Gas6, the product of growth arrest-specific gene 6, in atherosclerotic lesion development is put into perspective.", "text_with_entity_marker": "In addition, a possible role for [E1]Gas6[/E1], the product of [E2]growth arrest-specific gene 6[/E2], in atherosclerotic lesion development is put into perspective.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gas6", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "growth arrest-specific gene 6", "entity_2_idx": [[54, 83]], "entity_2_idx_in_text_with_entity_marker": [67, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1343_AIMed.d160.s1343.p0", "text": "Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.", "text_with_entity_marker": "Identification of vascular endothelial growth factor determinants for binding [E1]KDR[/E1] and [E2]FLT-1[/E2] receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[86, 91]], "entity_2_idx_in_text_with_entity_marker": [99, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1343_AIMed.d160.s1343.p1", "text": "Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.", "text_with_entity_marker": "Identification of vascular endothelial growth factor determinants for binding [E1]KDR[/E1] and FLT-1 receptors. Generation of receptor-selective [E2]VEGF[/E2] variants by site-directed mutagenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[136, 140]], "entity_2_idx_in_text_with_entity_marker": [149, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1343_AIMed.d160.s1343.p2", "text": "Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.", "text_with_entity_marker": "Identification of vascular endothelial growth factor determinants for binding KDR and [E1]FLT-1[/E1] receptors. Generation of receptor-selective [E2]VEGF[/E2] variants by site-directed mutagenesis.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FLT-1", "entity_1_idx": [[86, 91]], "entity_1_idx_in_text_with_entity_marker": [90, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[136, 140]], "entity_2_idx_in_text_with_entity_marker": [149, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1344_AIMed.d160.s1344.p0", "text": "Vascular endothelial growth factor (VEGF) expression in various cell types is induced by hypoxia and other stimuli.", "text_with_entity_marker": "[E1]Vascular endothelial growth factor[/E1] ([E2]VEGF[/E2]) expression in various cell types is induced by hypoxia and other stimuli.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Vascular endothelial growth factor", "entity_1_idx": [[0, 34]], "entity_1_idx_in_text_with_entity_marker": [4, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[36, 40]], "entity_2_idx_in_text_with_entity_marker": [49, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p0", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E2]kinase insert domain-containing receptor[/E2] (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "kinase insert domain-containing receptor", "entity_2_idx": [[139, 179]], "entity_2_idx_in_text_with_entity_marker": [152, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p1", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E2]KDR[/E2])/fetal liver kinase 1 (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p2", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/[E2]fetal liver kinase 1[/E2] (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fetal liver kinase 1", "entity_2_idx": [[186, 206]], "entity_2_idx_in_text_with_entity_marker": [199, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p3", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p4", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "[E1]VEGF[/E1] mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p5", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] ([E2]KDR[/E2])/fetal liver kinase 1 (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[181, 184]], "entity_2_idx_in_text_with_entity_marker": [194, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p6", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] (KDR)/[E2]fetal liver kinase 1[/E2] (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fetal liver kinase 1", "entity_2_idx": [[186, 206]], "entity_2_idx_in_text_with_entity_marker": [199, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p7", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] (KDR)/fetal liver kinase 1 ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p8", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, [E1]kinase insert domain-containing receptor[/E1] (KDR)/fetal liver kinase 1 (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "kinase insert domain-containing receptor", "entity_1_idx": [[139, 179]], "entity_1_idx_in_text_with_entity_marker": [143, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p9", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E1]KDR[/E1])/[E2]fetal liver kinase 1[/E2] (Flk-1) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[181, 184]], "entity_1_idx_in_text_with_entity_marker": [185, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "fetal liver kinase 1", "entity_2_idx": [[186, 206]], "entity_2_idx_in_text_with_entity_marker": [199, 219], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p10", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E1]KDR[/E1])/fetal liver kinase 1 ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[181, 184]], "entity_1_idx_in_text_with_entity_marker": [185, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p11", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor ([E1]KDR[/E1])/fetal liver kinase 1 (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[181, 184]], "entity_1_idx_in_text_with_entity_marker": [185, 188], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p12", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/[E1]fetal liver kinase 1[/E1] ([E2]Flk-1[/E2]) and FLT-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "fetal liver kinase 1", "entity_1_idx": [[186, 206]], "entity_1_idx_in_text_with_entity_marker": [190, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[208, 213]], "entity_2_idx_in_text_with_entity_marker": [221, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p13", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/[E1]fetal liver kinase 1[/E1] (Flk-1) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "fetal liver kinase 1", "entity_1_idx": [[186, 206]], "entity_1_idx_in_text_with_entity_marker": [190, 210], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1345_AIMed.d160.s1345.p14", "text": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 (Flk-1) and FLT-1.", "text_with_entity_marker": "VEGF mediates endothelial cell proliferation, angiogenesis, vascular growth, and vascular permeability via the endothelial cell receptors, kinase insert domain-containing receptor (KDR)/fetal liver kinase 1 ([E1]Flk-1[/E1]) and [E2]FLT-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flk-1", "entity_1_idx": [[208, 213]], "entity_1_idx_in_text_with_entity_marker": [212, 217], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[219, 224]], "entity_2_idx_in_text_with_entity_marker": [232, 237], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1346_AIMed.d160.s1346.p0", "text": "Alanine-scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR/Flk-1.", "text_with_entity_marker": "Alanine-scanning mutagenesis was used to identify a positively charged surface in [E1]VEGF[/E1] that mediates binding to [E2]KDR[/E2]/Flk-1.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[82, 86]], "entity_1_idx_in_text_with_entity_marker": [86, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1346_AIMed.d160.s1346.p1", "text": "Alanine-scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR/Flk-1.", "text_with_entity_marker": "Alanine-scanning mutagenesis was used to identify a positively charged surface in [E1]VEGF[/E1] that mediates binding to KDR/[E2]Flk-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[82, 86]], "entity_1_idx_in_text_with_entity_marker": [86, 90], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1346_AIMed.d160.s1346.p2", "text": "Alanine-scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to KDR/Flk-1.", "text_with_entity_marker": "Alanine-scanning mutagenesis was used to identify a positively charged surface in VEGF that mediates binding to [E1]KDR[/E1]/[E2]Flk-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[112, 115]], "entity_1_idx_in_text_with_entity_marker": [116, 119], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[116, 121]], "entity_2_idx_in_text_with_entity_marker": [129, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1347_AIMed.d160.s1347.p0", "text": "Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding KDR/Flk-1, while negatively charged residues, Asp63, Glu64, and Glu67, were associated with FLT-1 binding.", "text_with_entity_marker": "Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding [E1]KDR[/E1]/[E2]Flk-1[/E2], while negatively charged residues, Asp63, Glu64, and Glu67, were associated with FLT-1 binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Flk-1", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1347_AIMed.d160.s1347.p1", "text": "Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding KDR/Flk-1, while negatively charged residues, Asp63, Glu64, and Glu67, were associated with FLT-1 binding.", "text_with_entity_marker": "Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding [E1]KDR[/E1]/Flk-1, while negatively charged residues, Asp63, Glu64, and Glu67, were associated with [E2]FLT-1[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[181, 186]], "entity_2_idx_in_text_with_entity_marker": [194, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1347_AIMed.d160.s1347.p2", "text": "Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding KDR/Flk-1, while negatively charged residues, Asp63, Glu64, and Glu67, were associated with FLT-1 binding.", "text_with_entity_marker": "Arg82, Lys84 and His86, located in a hairpin loop, were found to be critical for binding KDR/[E1]Flk-1[/E1], while negatively charged residues, Asp63, Glu64, and Glu67, were associated with [E2]FLT-1[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Flk-1", "entity_1_idx": [[93, 98]], "entity_1_idx_in_text_with_entity_marker": [97, 102], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[181, 186]], "entity_2_idx_in_text_with_entity_marker": [194, 199], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1348_AIMed.d160.s1348.p0", "text": "A VEGF model based on PDGFb indicated these positively and negatively charged regions are distal in the monomer but are spatially close in the dimer.", "text_with_entity_marker": "A [E1]VEGF[/E1] model based on [E2]PDGFb[/E2] indicated these positively and negatively charged regions are distal in the monomer but are spatially close in the dimer.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "VEGF", "entity_1_idx": [[2, 6]], "entity_1_idx_in_text_with_entity_marker": [6, 10], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PDGFb", "entity_2_idx": [[22, 27]], "entity_2_idx_in_text_with_entity_marker": [35, 40], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1349_AIMed.d160.s1349.p0", "text": "Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.", "text_with_entity_marker": "Mutations within the [E1]KDR[/E1] site had minimal effect on [E2]FLT-1[/E2] binding, and mutants deficient in FLT-1 binding did not affect KDR binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[52, 57]], "entity_2_idx_in_text_with_entity_marker": [65, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1349_AIMed.d160.s1349.p1", "text": "Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.", "text_with_entity_marker": "Mutations within the [E1]KDR[/E1] site had minimal effect on FLT-1 binding, and mutants deficient in [E2]FLT-1[/E2] binding did not affect KDR binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1349_AIMed.d160.s1349.p2", "text": "Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.", "text_with_entity_marker": "Mutations within the [E1]KDR[/E1] site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect [E2]KDR[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1349_AIMed.d160.s1349.p3", "text": "Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.", "text_with_entity_marker": "Mutations within the KDR site had minimal effect on [E1]FLT-1[/E1] binding, and mutants deficient in [E2]FLT-1[/E2] binding did not affect KDR binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FLT-1", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[92, 97]], "entity_2_idx_in_text_with_entity_marker": [105, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1349_AIMed.d160.s1349.p4", "text": "Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.", "text_with_entity_marker": "Mutations within the KDR site had minimal effect on [E1]FLT-1[/E1] binding, and mutants deficient in FLT-1 binding did not affect [E2]KDR[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FLT-1", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1349_AIMed.d160.s1349.p5", "text": "Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in FLT-1 binding did not affect KDR binding.", "text_with_entity_marker": "Mutations within the KDR site had minimal effect on FLT-1 binding, and mutants deficient in [E1]FLT-1[/E1] binding did not affect [E2]KDR[/E2] binding.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FLT-1", "entity_1_idx": [[92, 97]], "entity_1_idx_in_text_with_entity_marker": [96, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "KDR", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1350_AIMed.d160.s1350.p0", "text": "Endothelial cell mitogenesis was abolished in mutants lacking KDR affinity; however, FLT-1 deficient mutants induced normal proliferation.", "text_with_entity_marker": "Endothelial cell mitogenesis was abolished in mutants lacking [E1]KDR[/E1] affinity; however, [E2]FLT-1[/E2] deficient mutants induced normal proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[62, 65]], "entity_1_idx_in_text_with_entity_marker": [66, 69], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[85, 90]], "entity_2_idx_in_text_with_entity_marker": [98, 103], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1352_AIMed.d160.s1352.p0", "text": "Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.", "text_with_entity_marker": "Furthermore, this mutational analysis implicates [E1]KDR[/E1], but not [E2]FLT-1[/E2], in VEGF induction of endothelial cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FLT-1", "entity_2_idx": [[62, 67]], "entity_2_idx_in_text_with_entity_marker": [75, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1352_AIMed.d160.s1352.p1", "text": "Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.", "text_with_entity_marker": "Furthermore, this mutational analysis implicates [E1]KDR[/E1], but not FLT-1, in [E2]VEGF[/E2] induction of endothelial cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "KDR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[72, 76]], "entity_2_idx_in_text_with_entity_marker": [85, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d160.s1352_AIMed.d160.s1352.p2", "text": "Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation.", "text_with_entity_marker": "Furthermore, this mutational analysis implicates KDR, but not [E1]FLT-1[/E1], in [E2]VEGF[/E2] induction of endothelial cell proliferation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FLT-1", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VEGF", "entity_2_idx": [[72, 76]], "entity_2_idx_in_text_with_entity_marker": [85, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s532_AIMed.d61.s532.p0", "text": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.", "text_with_entity_marker": "An expression plasmid encoding the human 75-kDa [E1]tumor necrosis factor (TNF) type 2 receptor[/E1] ([E2]TNF-R2[/E2]) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor (TNF) type 2 receptor", "entity_1_idx": [[48, 91]], "entity_1_idx_in_text_with_entity_marker": [52, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[93, 99]], "entity_2_idx_in_text_with_entity_marker": [106, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s532_AIMed.d61.s532.p1", "text": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.", "text_with_entity_marker": "An expression plasmid encoding the human 75-kDa [E1]tumor necrosis factor (TNF) type 2 receptor[/E1] (TNF-R2) was constructed and used to generate a stable human cell line (293/[E2]TNF-R2[/E2]) overexpressing TNF-R2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor (TNF) type 2 receptor", "entity_1_idx": [[48, 91]], "entity_1_idx_in_text_with_entity_marker": [52, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s532_AIMed.d61.s532.p2", "text": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.", "text_with_entity_marker": "An expression plasmid encoding the human 75-kDa [E1]tumor necrosis factor (TNF) type 2 receptor[/E1] (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing [E2]TNF-R2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "tumor necrosis factor (TNF) type 2 receptor", "entity_1_idx": [[48, 91]], "entity_1_idx_in_text_with_entity_marker": [52, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[191, 197]], "entity_2_idx_in_text_with_entity_marker": [204, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s532_AIMed.d61.s532.p3", "text": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.", "text_with_entity_marker": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor ([E1]TNF-R2[/E1]) was constructed and used to generate a stable human cell line (293/[E2]TNF-R2[/E2]) overexpressing TNF-R2.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[93, 99]], "entity_1_idx_in_text_with_entity_marker": [97, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[168, 174]], "entity_2_idx_in_text_with_entity_marker": [181, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s532_AIMed.d61.s532.p4", "text": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.", "text_with_entity_marker": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor ([E1]TNF-R2[/E1]) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing [E2]TNF-R2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[93, 99]], "entity_1_idx_in_text_with_entity_marker": [97, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[191, 197]], "entity_2_idx_in_text_with_entity_marker": [204, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s532_AIMed.d61.s532.p5", "text": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/TNF-R2) overexpressing TNF-R2.", "text_with_entity_marker": "An expression plasmid encoding the human 75-kDa tumor necrosis factor (TNF) type 2 receptor (TNF-R2) was constructed and used to generate a stable human cell line (293/[E1]TNF-R2[/E1]) overexpressing [E2]TNF-R2[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[168, 174]], "entity_1_idx_in_text_with_entity_marker": [172, 178], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[191, 197]], "entity_2_idx_in_text_with_entity_marker": [204, 210], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s533_AIMed.d61.s533.p0", "text": "Ligand binding analysis revealed high affinity binding (Kd = 0.2 nM) with approximately 94,000 +/- 7,500 sites/cell for 125I-TNF-alpha and approximately 5-fold lower affinity for TNF-beta (Kd = 1.1 nM) with 264,000 +/- 2,000 sites/cell.", "text_with_entity_marker": "Ligand binding analysis revealed high affinity binding (Kd = 0.2 nM) with approximately 94,000 +/- 7,500 sites/cell for 125I-[E1]TNF-alpha[/E1] and approximately 5-fold lower affinity for [E2]TNF-beta[/E2] (Kd = 1.1 nM) with 264,000 +/- 2,000 sites/cell.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[125, 134]], "entity_1_idx_in_text_with_entity_marker": [129, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[179, 187]], "entity_2_idx_in_text_with_entity_marker": [192, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p0", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-[E1]TNF-alpha[/E1] and 125I-[E2]TNF-beta[/E2] to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[22, 31]], "entity_1_idx_in_text_with_entity_marker": [26, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[41, 49]], "entity_2_idx_in_text_with_entity_marker": [54, 62], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p1", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-[E1]TNF-alpha[/E1] and 125I-TNF-beta to 293/[E2]TNF-R2[/E2] cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[22, 31]], "entity_1_idx_in_text_with_entity_marker": [26, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[57, 63]], "entity_2_idx_in_text_with_entity_marker": [70, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p2", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-[E1]TNF-alpha[/E1] and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for [E2]TNF-alpha[/E2] and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[22, 31]], "entity_1_idx_in_text_with_entity_marker": [26, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-alpha", "entity_2_idx": [[147, 156]], "entity_2_idx_in_text_with_entity_marker": [160, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p3", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-[E1]TNF-alpha[/E1] and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for [E2]TNF-beta[/E2], suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[22, 31]], "entity_1_idx_in_text_with_entity_marker": [26, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[185, 193]], "entity_2_idx_in_text_with_entity_marker": [198, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p4", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-[E1]TNF-alpha[/E1] and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three [E2]TNF-R2[/E2] molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[22, 31]], "entity_1_idx_in_text_with_entity_marker": [26, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[243, 249]], "entity_2_idx_in_text_with_entity_marker": [256, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p5", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-[E1]TNF-beta[/E1] to 293/[E2]TNF-R2[/E2] cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-beta", "entity_1_idx": [[41, 49]], "entity_1_idx_in_text_with_entity_marker": [45, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[57, 63]], "entity_2_idx_in_text_with_entity_marker": [70, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p6", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-[E1]TNF-beta[/E1] to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for [E2]TNF-alpha[/E2] and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-beta", "entity_1_idx": [[41, 49]], "entity_1_idx_in_text_with_entity_marker": [45, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-alpha", "entity_2_idx": [[147, 156]], "entity_2_idx_in_text_with_entity_marker": [160, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p7", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-[E1]TNF-beta[/E1] to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for [E2]TNF-beta[/E2], suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-beta", "entity_1_idx": [[41, 49]], "entity_1_idx_in_text_with_entity_marker": [45, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[185, 193]], "entity_2_idx_in_text_with_entity_marker": [198, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p8", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-[E1]TNF-beta[/E1] to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three [E2]TNF-R2[/E2] molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-beta", "entity_1_idx": [[41, 49]], "entity_1_idx_in_text_with_entity_marker": [45, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[243, 249]], "entity_2_idx_in_text_with_entity_marker": [256, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p9", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/[E1]TNF-R2[/E1] cells yielded predominant complexes with apparent molecular weights of 211,000 for [E2]TNF-alpha[/E2] and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[57, 63]], "entity_1_idx_in_text_with_entity_marker": [61, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-alpha", "entity_2_idx": [[147, 156]], "entity_2_idx_in_text_with_entity_marker": [160, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p10", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/[E1]TNF-R2[/E1] cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for [E2]TNF-beta[/E2], suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[57, 63]], "entity_1_idx_in_text_with_entity_marker": [61, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[185, 193]], "entity_2_idx_in_text_with_entity_marker": [198, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p11", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/[E1]TNF-R2[/E1] cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three [E2]TNF-R2[/E2] molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[57, 63]], "entity_1_idx_in_text_with_entity_marker": [61, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[243, 249]], "entity_2_idx_in_text_with_entity_marker": [256, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p12", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for [E1]TNF-alpha[/E1] and 205,000 and 244,000 for [E2]TNF-beta[/E2], suggesting these complexes contain two or three TNF-R2 molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[147, 156]], "entity_1_idx_in_text_with_entity_marker": [151, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[185, 193]], "entity_2_idx_in_text_with_entity_marker": [198, 206], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p13", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for [E1]TNF-alpha[/E1] and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three [E2]TNF-R2[/E2] molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[147, 156]], "entity_1_idx_in_text_with_entity_marker": [151, 160], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[243, 249]], "entity_2_idx_in_text_with_entity_marker": [256, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s534_AIMed.d61.s534.p14", "text": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for TNF-beta, suggesting these complexes contain two or three TNF-R2 molecules.", "text_with_entity_marker": "Cross-linking of 125I-TNF-alpha and 125I-TNF-beta to 293/TNF-R2 cells yielded predominant complexes with apparent molecular weights of 211,000 for TNF-alpha and 205,000 and 244,000 for [E1]TNF-beta[/E1], suggesting these complexes contain two or three [E2]TNF-R2[/E2] molecules.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-beta", "entity_1_idx": [[185, 193]], "entity_1_idx_in_text_with_entity_marker": [189, 197], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[243, 249]], "entity_2_idx_in_text_with_entity_marker": [256, 262], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s535_AIMed.d61.s535.p0", "text": "Immunoprecipitation of TNF-R2 from 32P-labeled 293/TNF-R2 cells demonstrated that the receptor is phosphorylated.", "text_with_entity_marker": "Immunoprecipitation of [E1]TNF-R2[/E1] from 32P-labeled 293/[E2]TNF-R2[/E2] cells demonstrated that the receptor is phosphorylated.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[23, 29]], "entity_1_idx_in_text_with_entity_marker": [27, 33], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[51, 57]], "entity_2_idx_in_text_with_entity_marker": [64, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s537_AIMed.d61.s537.p0", "text": "TNF-alpha treatment of 293/TNF-R2 cells did not significantly affect the degree or pattern of phosphorylation.", "text_with_entity_marker": "[E1]TNF-alpha[/E1] treatment of 293/[E2]TNF-R2[/E2] cells did not significantly affect the degree or pattern of phosphorylation.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-R2", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s539_AIMed.d61.s539.p0", "text": "Shedding of the extracellular domain of TNF-R2 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.", "text_with_entity_marker": "Shedding of the extracellular domain of [E1]TNF-R2[/E1] was induced by 4 beta-phorbol 12-myristate 13-acetate but not by [E2]TNF-alpha[/E2] or TNF-beta.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[40, 46]], "entity_1_idx_in_text_with_entity_marker": [44, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-alpha", "entity_2_idx": [[112, 121]], "entity_2_idx_in_text_with_entity_marker": [125, 134], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s539_AIMed.d61.s539.p1", "text": "Shedding of the extracellular domain of TNF-R2 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.", "text_with_entity_marker": "Shedding of the extracellular domain of [E1]TNF-R2[/E1] was induced by 4 beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or [E2]TNF-beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-R2", "entity_1_idx": [[40, 46]], "entity_1_idx_in_text_with_entity_marker": [44, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[125, 133]], "entity_2_idx_in_text_with_entity_marker": [138, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d61.s539_AIMed.d61.s539.p2", "text": "Shedding of the extracellular domain of TNF-R2 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by TNF-alpha or TNF-beta.", "text_with_entity_marker": "Shedding of the extracellular domain of TNF-R2 was induced by 4 beta-phorbol 12-myristate 13-acetate but not by [E1]TNF-alpha[/E1] or [E2]TNF-beta[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TNF-alpha", "entity_1_idx": [[112, 121]], "entity_1_idx_in_text_with_entity_marker": [116, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNF-beta", "entity_2_idx": [[125, 133]], "entity_2_idx_in_text_with_entity_marker": [138, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1817_AIMed.d210.s1817.p0", "text": "Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.", "text_with_entity_marker": "Cross-family interaction between the bHLHZip [E1]USF[/E1] and bZip [E2]Fra1[/E2] proteins results in down-regulation of AP1 activity.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "USF", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fra1", "entity_2_idx": [[58, 62]], "entity_2_idx_in_text_with_entity_marker": [71, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1817_AIMed.d210.s1817.p1", "text": "Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.", "text_with_entity_marker": "Cross-family interaction between the bHLHZip [E1]USF[/E1] and bZip Fra1 proteins results in down-regulation of [E2]AP1[/E2] activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AP1", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1817_AIMed.d210.s1817.p2", "text": "Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.", "text_with_entity_marker": "Cross-family interaction between the bHLHZip USF and bZip [E1]Fra1[/E1] proteins results in down-regulation of [E2]AP1[/E2] activity.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra1", "entity_1_idx": [[58, 62]], "entity_1_idx_in_text_with_entity_marker": [62, 66], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AP1", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1819_AIMed.d210.s1819.p0", "text": "To further examine the function of the bHLHZip protein, USF, we screened for cellular proteins which could directly interact with USF using the yeast two-hybrid system.", "text_with_entity_marker": "To further examine the function of the bHLHZip protein, [E1]USF[/E1], we screened for cellular proteins which could directly interact with [E2]USF[/E2] using the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[130, 133]], "entity_2_idx_in_text_with_entity_marker": [143, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1820_AIMed.d210.s1820.p0", "text": "A bZip protein, Fra1, was found to efficiently interact with USF.", "text_with_entity_marker": "A bZip protein, [E1]Fra1[/E1], was found to efficiently interact with [E2]USF[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fra1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[61, 64]], "entity_2_idx_in_text_with_entity_marker": [74, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p0", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "[E1]USF[/E1] specifically interacts with [E2]Fra1[/E2] but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "USF", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fra1", "entity_2_idx": [[32, 36]], "entity_2_idx_in_text_with_entity_marker": [45, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p1", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "[E1]USF[/E1] specifically interacts with Fra1 but not with other closely related family members, [E2]c-Fos[/E2], Fra2, FosB, or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p2", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "[E1]USF[/E1] specifically interacts with Fra1 but not with other closely related family members, c-Fos, [E2]Fra2[/E2], FosB, or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fra2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p3", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "[E1]USF[/E1] specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, [E2]FosB[/E2], or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FosB", "entity_2_idx": [[101, 105]], "entity_2_idx_in_text_with_entity_marker": [114, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p4", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "[E1]USF[/E1] specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with [E2]c-Jun[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p5", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with [E1]Fra1[/E1] but not with other closely related family members, [E2]c-Fos[/E2], Fra2, FosB, or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra1", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p6", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with [E1]Fra1[/E1] but not with other closely related family members, c-Fos, [E2]Fra2[/E2], FosB, or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra1", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fra2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p7", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with [E1]Fra1[/E1] but not with other closely related family members, c-Fos, Fra2, [E2]FosB[/E2], or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra1", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FosB", "entity_2_idx": [[101, 105]], "entity_2_idx_in_text_with_entity_marker": [114, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p8", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with [E1]Fra1[/E1] but not with other closely related family members, c-Fos, Fra2, FosB, or with [E2]c-Jun[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra1", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p9", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with Fra1 but not with other closely related family members, [E1]c-Fos[/E1], [E2]Fra2[/E2], FosB, or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fra2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p10", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with Fra1 but not with other closely related family members, [E1]c-Fos[/E1], Fra2, [E2]FosB[/E2], or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FosB", "entity_2_idx": [[101, 105]], "entity_2_idx_in_text_with_entity_marker": [114, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p11", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with Fra1 but not with other closely related family members, [E1]c-Fos[/E1], Fra2, FosB, or with [E2]c-Jun[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "c-Fos", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p12", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, [E1]Fra2[/E1], [E2]FosB[/E2], or with c-Jun.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra2", "entity_1_idx": [[95, 99]], "entity_1_idx_in_text_with_entity_marker": [99, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FosB", "entity_2_idx": [[101, 105]], "entity_2_idx_in_text_with_entity_marker": [114, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p13", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, [E1]Fra2[/E1], FosB, or with [E2]c-Jun[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra2", "entity_1_idx": [[95, 99]], "entity_1_idx_in_text_with_entity_marker": [99, 103], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1821_AIMed.d210.s1821.p14", "text": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.", "text_with_entity_marker": "USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, [E1]FosB[/E1], or with [E2]c-Jun[/E2].", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "FosB", "entity_1_idx": [[101, 105]], "entity_1_idx_in_text_with_entity_marker": [105, 109], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1822_AIMed.d210.s1822.p0", "text": "Both the bHLHZip and the N-terminal regions of Fra1 are required for efficient interaction with USF.", "text_with_entity_marker": "Both the bHLHZip and the N-terminal regions of [E1]Fra1[/E1] are required for efficient interaction with [E2]USF[/E2].", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Fra1", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1823_AIMed.d210.s1823.p0", "text": "In vivo association between USF and Fra1 has been demonstrated by co-immunoprecipitation.", "text_with_entity_marker": "In vivo association between [E1]USF[/E1] and [E2]Fra1[/E2] has been demonstrated by co-immunoprecipitation.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "USF", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fra1", "entity_2_idx": [[36, 40]], "entity_2_idx_in_text_with_entity_marker": [49, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1824_AIMed.d210.s1824.p0", "text": "Expression of exogenous USF led to a decrease in AP1-dependent transcription in F9 cells.", "text_with_entity_marker": "Expression of exogenous [E1]USF[/E1] led to a decrease in [E2]AP1[/E2]-dependent transcription in F9 cells.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "USF", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AP1", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1825_AIMed.d210.s1825.p0", "text": "Co-expression of exogenous Fra1 restored the AP1 activity in a dose-dependent manner.", "text_with_entity_marker": "Co-expression of exogenous [E1]Fra1[/E1] restored the [E2]AP1[/E2] activity in a dose-dependent manner.", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Fra1", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AP1", "entity_2_idx": [[45, 48]], "entity_2_idx_in_text_with_entity_marker": [58, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1826_AIMed.d210.s1826.p0", "text": "These data show that USF and Fra1 physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.", "text_with_entity_marker": "These data show that [E1]USF[/E1] and [E2]Fra1[/E2] physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "USF", "entity_1_idx": [[21, 24]], "entity_1_idx_in_text_with_entity_marker": [25, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fra1", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
